VIR NASDAQ
Vir Biotechnology, Inc.
1W: +7.7%
1M: +10.1%
3M: +33.9%
YTD: +94.8%
1Y: +93.5%
3Y: +36.9%
5Y: -71.3%
$11.93
+0.36 (+3.11%)
After Hours: $11.46 (-0.46, -3.90%)
Weekly Expected Move ±7.6%
$9
$10
$11
$11
$12
Credit Risk of going bust: lower than 57% of companies Debt: 4.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.07 (down 99.4%), Vir Biotechnology, Inc. would be worth roughly what it owes.
Total debt $93.3M against a stock market value of $1.96B.
Distance to default 5.86 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $46.6M (short-term plus half of long-term), stock volatility 63.1%; Altman Z'' 2.27. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.07 (down 99.4%), Vir Biotechnology, Inc. would be worth roughly what it owes.
Total debt $93.3M against a stock market value of $1.96B.
Distance to default 5.86 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $46.6M (short-term plus half of long-term), stock volatility 63.1%; Altman Z'' 2.27. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
#174
of 1061
Biotechnology
Technical Signal Map
111 Bullish
16 Neutral
142 Bearish
VIR
$1.8B
Vir Biotechnology, Inc.
BULLISH
+91
KYMR
$9.1B
Kymera Therapeutics, Inc.
BULLISH
+100
CAI
$9.1B
Caris Life Sciences, Inc.
BULLISH
+100
SYRE
$8.3B
Spyre Therapeutics, Inc.
BULLISH
+100
MANE
$5.8B
Veradermics, Incorporated
BULLISH
+100
IRON
$2.9B
Disc Medicine, Inc.
BULLISH
+100
NRIX
$2.8B
Nurix Therapeutics, Inc.
BULLISH
+100
FTRE
$2.2B
Fortrea Holdings Inc.
BULLISH
+100
AUPH
$2.2B
Aurinia Pharmaceuticals Inc.
BULLISH
+100
AGIO
$2.2B
Agios Pharmaceuticals, Inc.
BULLISH
+100
ALMR
$2.1B
Alamar Biosciences, Inc.
BULLISH
+100
MRVI
$2.1B
Maravai LifeSciences Holdings, Inc.
BULLISH
+100
SEPN
$1.9B
Septerna Inc
BULLISH
+100
KLRA
$1.7B
Kailera Therapeutics, Inc.
BULLISH
+100
COAG
$1.6B
Hemab Therapeutics Holdings, Inc. Common Stock
BULLISH
+100
REPL
$1.1B
Replimune Group, Inc.
BULLISH
+100
RIGL
$900M
Rigel Pharmaceuticals, Inc.
BULLISH
+100
SOLTF
$770M
Nxera Pharma Co., Ltd.
BULLISH
+100
CRMD
$610M
CorMedix Inc.
BULLISH
+100
DMAC
$470M
DiaMedica Therapeutics Inc.
BULLISH
+100
SGMT
$310M
Sagimet Biosciences Inc.
BULLISH
+100
ARQT
$3.9B
Arcutis Biotherapeutics, Inc.
BULLISH
+91
BVNRY
$2.9B
Bavarian Nordic A/S
BULLISH
+91
ONTTF
$2.7B
Oxford Nanopore Technologies plc
BULLISH
+91
LKFT
$2.1B
Lakefront Biotherapeutics N.V.
BULLISH
+91
SGP
$950M
SpyGlass Pharma, Inc. Common Stock
BULLISH
+91
VSTM
$910M
Verastem, Inc.
BULLISH
+91
VRDN
$2.5B
Viridian Therapeutics, Inc.
BULLISH
+87
ADMA
$2.4B
ADMA Biologics, Inc.
BULLISH
+87
MAZE
$1.7B
Maze Therapeutics, Inc.
BULLISH
+87
PRME
$670M
Prime Medicine, Inc.
BULLISH
+87
XFOR
$320M
X4 Pharmaceuticals, Inc.
BULLISH
+87
LEGN
$3.6B
Legend Biotech Corporation
BULLISH
+84
BEAM
$2.5B
Beam Therapeutics Inc.
BULLISH
+84
PVLA
$1.8B
Palvella Therapeutics, Inc.
BULLISH
+84
RARE
$1.5B
Ultragenyx Pharmaceutical Inc.
BULLISH
+84
OABIW
$1.1B
OmniAb, Inc.
BULLISH
+84
EDIT
$370M
Editas Medicine, Inc.
BULLISH
+84
INDP
$360M
Indaptus Therapeutics, Inc.
BULLISH
+84
GENB
$1.6B
Generate Biomedicines, Inc.
BULLISH
+80
RXRX
$2.0B
Recursion Pharmaceuticals, Inc.
BULLISH
+78
TGTX
$8.3B
TG Therapeutics, Inc.
BULLISH
+75
LGND
$6.0B
Ligand Pharmaceuticals Incorporated
BULLISH
+75
ORKA
$5.3B
Oruka Therapeutics, Inc.
BULLISH
+75
RLAY
$4.0B
Relay Therapeutics, Inc.
BULLISH
+75
BHVN
$2.1B
Biohaven Ltd.
BULLISH
+75
ZYME
$2.0B
Zymeworks Inc.
BULLISH
+75
ABSI
$1.6B
Absci Corporation
BULLISH
+75
NTLA
$1.6B
Intellia Therapeutics, Inc.
BULLISH
+75
TRAX
$1.6B
First Tracks Biotherapeutics Inc
BULLISH
+75
LBRX
$1.2B
LB Pharmaceuticals Inc Common Stock
BULLISH
+75
ENTX
$510M
Entera Bio Ltd.
BULLISH
+75
ELVN
$3.0B
Enliven Therapeutics, Inc.
BULLISH
+73
NAUT
$410M
Nautilus Biotechnolgy, Inc.
BULLISH
+69
COGT
$5.4B
Cogent Biosciences, Inc.
BULLISH
+68
ADPT
$4.1B
Adaptive Biotechnologies Corporation
BULLISH
+68
PRTA
$420M
Prothena Corporation plc
BULLISH
+68
KOD
$5.5B
Kodiak Sciences Inc.
BULLISH
+66
XNCR
$1.9B
Xencor, Inc.
BULLISH
+66
SRPT
$1.9B
Sarepta Therapeutics, Inc.
BULLISH
+66
XERS
$1.9B
Xeris Biopharma Holdings, Inc.
BULLISH
+66
SPTX
$1.1B
Seaport Therapeutics, Inc. Common Stock
BULLISH
+66
SLN
$930M
Silence Therapeutics plc
BULLISH
+66
VCEL
$2.2B
Vericel Corporation
BULLISH
+65
NBTX
$1.5B
Nanobiotix S.A.
BULLISH
+62
MLTX
$1.0B
MoonLake Immunotherapeutics
BULLISH
+62
STOK
$1.6B
Stoke Therapeutics, Inc.
BULLISH
+59
PHAR
$710M
Pharming Group N.V.
BULLISH
+59
CCCC
$380M
C4 Therapeutics, Inc.
BULLISH
+59
NGNE
$370M
Neurogene Inc.
BULLISH
+59
FENC
$350M
Fennec Pharmaceuticals Inc.
BULLISH
+59
PBYI
$570M
Puma Biotechnology, Inc.
BULLISH
+58
AKBLF
$7.4B
ALK-Abelló A/S
BULLISH
+53
ERAS
$5.0B
Erasca, Inc.
BULLISH
+52
IMCR
$1.6B
Immunocore Holdings plc
BULLISH
+50
JANX
$1.0B
Janux Therapeutics, Inc.
BULLISH
+50
PHVS
$2.2B
Pharvaris N.V.
BULLISH
+43
ZBIO
$1.8B
Zenas BioPharma, Inc.
BULLISH
+43
VOR
$990M
Vor Biopharma Inc.
BULLISH
+43
DRUG
$520M
Bright Minds Biosciences Inc.
BULLISH
+43
BRVE
$1.5B
Braveheart Bio, Inc.
BULLISH
+40
DMRA
$1.3B
Damora Therapeutics, Inc.
BULLISH
+40
PTCHF
$390M
PureTech Health plc
BULLISH
+40
TYRA
$1.2B
Tyra Biosciences, Inc.
BULLISH
+36
ARVN
$470M
Arvinas, Inc.
BULLISH
+36
KURA
$850M
Kura Oncology, Inc.
BULLISH
+34
RZLT
$370M
Rezolute, Inc.
BULLISH
+34
OBIO
$340M
Orchestra BioMed Holdings, Inc.
BULLISH
+34
DYN
$2.9B
Dyne Therapeutics, Inc.
BULLISH
+33
DNA
$670M
Ginkgo Bioworks Holdings, Inc.
BULLISH
+32
ACAD
$3.4B
Acadia Pharmaceuticals Inc.
LEAN BULL
+29
QURE
$1.6B
uniQure N.V.
LEAN BULL
+29
IOVA
$6.4B
Iovance Biotherapeutics, Inc.
LEAN BULL
+28
PTGX
$9.0B
Protagonist Therapeutics, Inc.
LEAN BULL
+27
MIRM
$5.2B
Mirum Pharmaceuticals, Inc.
LEAN BULL
+27
DFTX
$4.8B
Definium Therapeutics, Inc.
LEAN BULL
+27
VERA
$2.0B
Vera Therapeutics, Inc.
LEAN BULL
+27
BCRX
$1.9B
BioCryst Pharmaceuticals, Inc.
LEAN BULL
+27
CMPS
$1.6B
COMPASS Pathways plc
LEAN BULL
+27
OVID
$420M
Ovid Therapeutics Inc.
LEAN BULL
+27
ABCL
$3.8B
AbCellera Biologics Inc.
LEAN BULL
+26
ANAB
$1.5B
AnaptysBio, Inc.
LEAN BULL
+22
TWST
$9.2B
Twist Bioscience Corporation
LEAN BULL
+18
PRAX
$7.1B
Praxis Precision Medicines, Inc.
LEAN BULL
+18
INVA
$1.5B
Innoviva, Inc.
LEAN BULL
+18
YDES
$350M
YD Bio Limited Ordinary Shares
LEAN BULL
+18
ZURA
$320M
Zura Bio Limited
LEAN BULL
+18
ACRS
$550M
Aclaris Therapeutics, Inc.
LEAN BULL
+16
WVE
$630M
Wave Life Sciences Ltd.
LEAN BULL
+13
EWTX
$4.2B
Edgewise Therapeutics, Inc.
LEAN BULL
+11
TXG
$9.3B
10x Genomics, Inc.
LEAN BULL
+10
CYDY
$380M
CytoDyn Inc.
NEUTRAL
+5
CGEM
$880M
Cullinan Therapeutics, Inc.
NEUTRAL
+4
BCHMF
$6.8B
Bachem Holding AG
NEUTRAL
+2
XENE
$3.4B
Xenon Pharmaceuticals Inc.
NEUTRAL
+2
PBLS
$3.0B
Parabilis Medicines, Inc.
NEUTRAL
+2
STTK
$550M
Shattuck Labs, Inc.
NEUTRAL
+1
LYCA
$1.6B
Lycia Therapeutics Inc.
N/A
0
ODTX
$940M
Odyssey Therapeutics, Inc.
NEUTRAL
-2
JBIO
$930M
Jade Biosciences, Inc.
NEUTRAL
-2
SVRA
$870M
Savara Inc.
NEUTRAL
-5
ALMS
$880M
Alumis Inc.
NEUTRAL
-6
CRSP
$4.8B
CRISPR Therapeutics AG
NEUTRAL
-7
ZLAB
$2.7B
Zai Lab Limited
NEUTRAL
-8
IONS
$7.1B
Ionis Pharmaceuticals, Inc.
NEUTRAL
-9
RYTM
$6.2B
Rhythm Pharmaceuticals, Inc.
NEUTRAL
-9
SRRK
$5.0B
Scholar Rock Holding Corporation
NEUTRAL
-9
GLPGF
$2.1B
Lakefront Biotherapeutics
LEAN BEAR
-12
CGON
$5.5B
CG Oncology Inc.
LEAN BEAR
-15
ENTA
$340M
Enanta Pharmaceuticals, Inc.
LEAN BEAR
-15
GYRE
$620M
Gyre Therapeutics, Inc.
LEAN BEAR
-16
TRVI
$1.8B
Trevi Therapeutics, Inc.
LEAN BEAR
-17
AURA
$650M
Aura Biosciences, Inc.
LEAN BEAR
-17
TTRX
$310M
Turn Therapeutics Inc.
LEAN BEAR
-17
DNTH
$4.3B
Dianthus Therapeutics, Inc.
LEAN BEAR
-18
SLDB
$630M
Solid Biosciences Inc.
LEAN BEAR
-18
HNGZY
$6.9B
Hangzhou Tigermed Consulting Co., Ltd
LEAN BEAR
-20
SHJBF
$4.8B
Shanghai Junshi Biosciences Co., Ltd.
LEAN BEAR
-20
PTCT
$5.1B
PTC Therapeutics, Inc.
LEAN BEAR
-22
CELC
$3.2B
Celcuity Inc.
LEAN BEAR
-22
TSHA
$1.3B
Taysha Gene Therapies, Inc.
LEAN BEAR
-22
MNKD
$1.0B
MannKind Corporation
LEAN BEAR
-23
KARD
$1.1B
Kardigan, Inc.
LEAN BEAR
-24
FDMT
$600M
4D Molecular Therapeutics, Inc.
LEAN BEAR
-24
FGHQF
$360M
Frontage Holdings Corporation
LEAN BEAR
-25
GWIN
$360M
Glorywin Entertainment Group, Inc.
LEAN BEAR
-25
NURPF
$1.8B
Neuren Pharmaceuticals Limited
LEAN BEAR
-26
IMNM
$2.1B
Immunome, Inc.
LEAN BEAR
-27
ADRX
$1.9B
ADARx Pharmaceuticals, Inc.
LEAN BEAR
-29
ANNX
$610M
Annexon, Inc.
BEARISH
-30
GLUE
$920M
Monte Rosa Therapeutics, Inc.
BEARISH
-31
SANA
$700M
Sana Biotechnology, Inc.
BEARISH
-31
OCS
$490M
Oculis Holding AG
BEARISH
-31
RLMD
$350M
Relmada Therapeutics, Inc.
BEARISH
-31
ALLO
$430M
Allogene Therapeutics, Inc.
BEARISH
-32
AAPG
$1.4B
Ascentage Pharma Group International
BEARISH
-33
SNBIF
$1.3B
SanBio Company Limited
BEARISH
-33
BPMUF
$960M
Basilea Pharmaceutica AG
BEARISH
-34
HRMY
$2.1B
Harmony Biosciences Holdings, Inc.
BEARISH
-35
CLYM
$590M
Climb Bio, Inc.
BEARISH
-35
MNPR
$470M
Monopar Therapeutics Inc.
BEARISH
-35
MEOBF
$2.0B
Mesoblast Limited
BEARISH
-37
PCVX
$9.5B
Vaxcyte, Inc.
BEARISH
-38
ARWR
$8.2B
Arrowhead Pharmaceuticals, Inc.
BEARISH
-40
AMLX
$3.4B
Amylyx Pharmaceuticals, Inc.
BEARISH
-40
MBX
$2.3B
MBX Biosciences, Inc. Common Stock
BEARISH
-40
MLYS
$1.8B
Mineralys Therapeutics, Inc.
BEARISH
-40
IMTX
$1.1B
Immatics N.V.
BEARISH
-40
AKTS
$850M
Aktis Oncology, Inc.
BEARISH
-40
ATTO
$630M
Attovia Therapeutics, Inc.
BEARISH
-40
OLMA
$560M
Olema Pharmaceuticals, Inc.
BEARISH
-40
BNTC
$300M
Benitec Biopharma Inc.
BEARISH
-40
TARS
$3.2B
Tarsus Pharmaceuticals, Inc.
BEARISH
-42
CSPHF
$1.4B
CStone Pharmaceuticals
BEARISH
-42
DRTSW
$1.2B
Alpha Tau Medical Ltd.
BEARISH
-42
GHRS
$1.2B
GH Research PLC
BEARISH
-43
DSGN
$640M
Design Therapeutics, Inc.
BEARISH
-43
HNSBF
$330M
Hansa Biopharma AB (publ)
BEARISH
-44
IDRSF
$1.4B
Idorsia Ltd
BEARISH
-47
VBIZF
$400M
Viva Biotech Holdings
BEARISH
-47
DNLI
$2.9B
Denali Therapeutics Inc.
BEARISH
-48
CASBF
$1.4B
CanSino Biologics Inc.
BEARISH
-48
CRVS
$890M
Corvus Pharmaceuticals, Inc.
BEARISH
-48
CLDX
$2.3B
Celldex Therapeutics, Inc.
BEARISH
-49
NKTR
$1.1B
Nektar Therapeutics
BEARISH
-49
RGNX
$440M
REGENXBIO Inc.
BEARISH
-49
BLSM
$430M
BlossomHill Therapeutics, Inc.
BEARISH
-49
TECX
$390M
Tectonic Therapeutic, Inc.
BEARISH
-49
TNGX
$3.9B
Tango Therapeutics, Inc.
BEARISH
-50
TLX
$3.1B
Telix Pharmaceuticals Limited
BEARISH
-50
PPTDF
$870M
PeptiDream Inc.
BEARISH
-50
IMVT
$5.9B
Immunovant, Inc.
BEARISH
-52
ANRO
$860M
Alto Neuroscience, Inc.
BEARISH
-52
ABUS
$830M
Arbutus Biopharma Corp
BEARISH
-52
GNNSF
$9.6B
Genscript Biotech Corporation
BEARISH
-53
NUVB
$1.6B
Nuvation Bio Inc.
BEARISH
-53
AUTL
$410M
Autolus Therapeutics plc
BEARISH
-53
OCUL
$1.4B
Ocular Therapeutix, Inc.
BEARISH
-56
OMER
$1.2B
Omeros Corporation
BEARISH
-58
AVBP
$1.0B
ArriVent BioPharma, Inc.
BEARISH
-58
EPRX
$450M
Eupraxia Pharmaceuticals Inc.
BEARISH
-58
IBRX
$8.7B
ImmunityBio, Inc.
BEARISH
-59
CAMRF
$3.7B
Camurus AB
BEARISH
-59
ORIC
$1.4B
ORIC Pharmaceuticals, Inc.
BEARISH
-59
RAPP
$1.2B
Rapport Therapeutics, Inc. Common Stock
BEARISH
-60
DRTS
$1.2B
Alpha Tau Medical Ltd
BEARISH
-60
MGTX
$880M
MeiraGTx Holdings plc
BEARISH
-60
RCUS
$2.3B
Arcus Biosciences, Inc.
BEARISH
-62
NAMS
$2.3B
NewAmsterdam Pharma Company N.V.
BEARISH
-65
AVLN
$1.1B
Avalyn Pharma Inc. Common Stock
BEARISH
-65
APMD
$790M
Apnimed, Inc.
BEARISH
-65
CBIO
$480M
Crescent Biopharma, Inc.
BEARISH
-65
KYTX
$330M
Kyverna Therapeutics, Inc.
BEARISH
-65
KRYS
$9.2B
Krystal Biotech, Inc.
BEARISH
-66
GERN
$720M
Geron Corporation
BEARISH
-66
ZVRA
$580M
Zevra Therapeutics, Inc.
BEARISH
-66
PHAT
$460M
Phathom Pharmaceuticals, Inc.
BEARISH
-66
FTH
$440M
Faeth Therapeutics, Inc.
BEARISH
-66
TVTX
$4.7B
Travere Therapeutics, Inc.
BEARISH
-69
NVAX
$1.6B
Novavax, Inc.
BEARISH
-69
NWPHF
$410M
Newron Pharmaceuticals S.p.A.
BEARISH
-71
SNDX
$1.2B
Syndax Pharmaceuticals, Inc.
BEARISH
-74
CTMX
$510M
CytomX Therapeutics, Inc.
BEARISH
-74
ASMB
$400M
Assembly Biosciences, Inc.
BEARISH
-74
MPLT
$340M
MapLight Therapeutics, Inc.
BEARISH
-74
IDYA
$3.4B
IDEAYA Biosciences, Inc.
BEARISH
-75
SLS
$2.3B
SELLAS Life Sciences Group, Inc.
BEARISH
-75
PGEN
$2.2B
Precigen, Inc.
BEARISH
-75
ASCLF
$770M
Ascletis Pharma Inc.
BEARISH
-75
ACHV
$670M
Achieve Life Sciences, Inc.
BEARISH
-75
NVCT
$650M
Nuvectis Pharma, Inc.
BEARISH
-75
BLTE
$5.9B
Belite Bio, Inc
BEARISH
-78
IMMX
$680M
Immix Biopharma, Inc.
BEARISH
-78
LXRX
$630M
Lexicon Pharmaceuticals, Inc.
BEARISH
-78
CADL
$610M
Candel Therapeutics, Inc.
BEARISH
-78
MDXG
$570M
MiMedx Group, Inc.
BEARISH
-78
AVIR
$320M
Atea Pharmaceuticals, Inc.
BEARISH
-78
CYTK
$8.5B
Cytokinetics, Incorporated
BEARISH
-82
HBMHF
$1.3B
HBM Holdings Limited
BEARISH
-82
GPCR
$1.2B
Structure Therapeutics Inc.
BEARISH
-82
ARDX
$770M
Ardelyx, Inc.
BEARISH
-82
SLBT
$640M
SL Science Holding Ltd
BEARISH
-82
PROK
$470M
ProKidney Corp.
BEARISH
-82
INBX
$1.4B
Inhibrx Biosciences Inc.
BEARISH
-84
URGN
$1.7B
UroGen Pharma Ltd.
BEARISH
-87
MDCLF
$1.1B
MedinCell S.A.
BEARISH
-87
ANL
$560M
Adlai Nortye Ltd.
BEARISH
-87
GNFTF
$470M
Genfit S.A.
BEARISH
-87
ARTV
$300M
Artiva Biotherapeutics, Inc.
BEARISH
-87
AXSM
$7.6B
Axsome Therapeutics, Inc.
BEARISH
-91
REGMF
$5.6B
RemeGen Co., Ltd.
BEARISH
-91
VKTX
$3.1B
Viking Therapeutics, Inc.
BEARISH
-91
GENSF
$1.8B
Genus plc
BEARISH
-91
AGMB
$450M
AgomAb Therapeutics N.V. American Depositary Shares
BEARISH
-91
AVCTF
$420M
Avacta Group Plc
BEARISH
-91
ALT
$410M
Altimmune, Inc.
BEARISH
-91
AVTX
$370M
Avalo Therapeutics, Inc.
BEARISH
-91
CAPR
$340M
Capricor Therapeutics, Inc.
BEARISH
-91
TRSBF
$4.3B
3SBio Inc.
BEARISH
-100
BRCTF
$2.6B
BioArctic AB
BEARISH
-100
ZLDPF
$2.4B
Zealand Pharma A/S
BEARISH
-100
INCPF
$2.4B
InnoCare Pharma Limited
BEARISH
-100
PHMMF
$1.6B
Pharma Mar, S.A.
BEARISH
-100
BCAX
$1.1B
Bicara Therapeutics Inc. Common Stock
BEARISH
-100
IVEVF
$750M
Inventiva S.A.
BEARISH
-100
INRLF
$640M
Valneva SE
BEARISH
-100
SPRY
$400M
ARS Pharmaceuticals, Inc.
BEARISH
-100
EIKN
$390M
Eikon Therapeutics, Inc. Common Stock
BEARISH
-100
DMTRF
$310M
3-D Matrix, Ltd.
BEARISH
-100
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology, Inc. | $1.8B | -6.4 | -26.1 | -38.8 | 33.5 | 1495.9 | 5 | BULLISH | 92.7 |
| KYMR Kymera Therapeutics, Inc. | $9.1B | -37.5 | -24.2 | -30.7 | -94.2 | 134.8 | 6 | BULLISH | 101.3 |
| CAI Caris Life Sciences, Inc. | $9.1B | 96.5 | 20.1 | 61.1 | -0.2 | 445.5 | 7 | BULLISH | 17.2 |
| SYRE Spyre Therapeutics, Inc. | $8.3B | -50.5 | -23.0 | 359.8 | — | — | 3 | BULLISH | 306.0 |
| MANE Veradermics, Incorporated | $5.8B | — | — | — | — | — | — | BULLISH | — |
| IRON Disc Medicine, Inc. | $2.9B | -12.6 | -39.1 | 1672.3 | — | — | 1 | BULLISH | -7.2 |
| NRIX Nurix Therapeutics, Inc. | $2.8B | 10.7 | 44.0 | -1896.6 | 81.7 | 738.8 | 8 | BULLISH | 127.5 |
| FTRE Fortrea Holdings Inc. | $2.2B | -27.4 | -15.3 | 0.6 | -1.9 | -2.1 | 6 | BULLISH | 149.1 |
| AUPH Aurinia Pharmaceuticals Inc. | $2.2B | 7.3 | 66.1 | 127.2 | 45.0 | 19.8 | 7 | BULLISH | 41.2 |
| AGIO Agios Pharmaceuticals, Inc. | $2.2B | -5.4 | -34.3 | -82.5 | -225.1 | 140.6 | 4 | BULLISH | -11.5 |
| ALMR Alamar Biosciences, Inc. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| MRVI Maravai LifeSciences Holdings, Inc. | $2.1B | -15.6 | -32.9 | 24.4 | -24.1 | -3.3 | 5 | BULLISH | 154.5 |
| SEPN Septerna Inc | $1.9B | -81.4 | -6.3 | -93.1 | -48.7 | 17878.5 | 5 | BULLISH | 95.6 |
| KLRA Kailera Therapeutics, Inc. | $1.7B | — | — | — | — | — | — | BULLISH | — |
| COAG Hemab Therapeutics Holdings, Inc. Common Stock | $1.6B | — | — | — | — | — | — | BULLISH | — |
| REPL Replimune Group, Inc. | $1.1B | -5.8 | -115.8 | -882.8 | — | — | 3 | BULLISH | 72.1 |
| RIGL Rigel Pharmaceuticals, Inc. | $900M | 2.9 | 126.9 | 88.5 | 22.0 | 3.3 | 4 | BULLISH | 71.5 |
| SOLTF Nxera Pharma Co., Ltd. | $770M | -16.2 | -12.0 | -1.7 | -2.6 | 7.5 | 4 | BULLISH | 38.2 |
| CRMD CorMedix Inc. | $610M | 3.4 | 54.9 | 57.2 | 25.5 | 280.5 | 5 | BULLISH | -25.8 |
| DMAC DiaMedica Therapeutics Inc. | $470M | -13.6 | -114.6 | 616.3 | — | — | 2 | BULLISH | 42.7 |
| SGMT Sagimet Biosciences Inc. | $310M | -8.3 | -24.4 | -231.4 | — | — | 3 | BULLISH | 24.9 |
| ARQT Arcutis Biotherapeutics, Inc. | $3.9B | 142.4 | 15.9 | 34.7 | 11.6 | 76.1 | 7 | BULLISH | 60.1 |
| BVNRY Bavarian Nordic A/S | $2.9B | 13.0 | 12.3 | 7.1 | 36.0 | -5.8 | 7 | BULLISH | 1.6 |
| ONTTF Oxford Nanopore Technologies plc | $2.7B | -18.7 | -25.6 | -36.2 | -41.1 | 14.4 | 4 | BULLISH | 57.6 |
| LKFT Lakefront Biotherapeutics N.V. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| SGP SpyGlass Pharma, Inc. Common Stock | $950M | — | — | — | — | — | — | BULLISH | — |
| VSTM Verastem, Inc. | $910M | -4.0 | -471.2 | 6197.3 | -86.5 | 3995.7 | 4 | BULLISH | 12.8 |
| VRDN Viridian Therapeutics, Inc. | $2.5B | -6.9 | -65.7 | 418.2 | -44760.2 | 23220.3 | 4 | BULLISH | 7.7 |
| ADMA ADMA Biologics, Inc. | $2.4B | 15.5 | 41.9 | 35.5 | 30.4 | 8.0 | 5 | BULLISH | -27.7 |
| MAZE Maze Therapeutics, Inc. | $1.7B | -11.5 | -37.3 | -112.3 | — | — | 3 | BULLISH | 2.4 |
| PRME Prime Medicine, Inc. | $670M | -4.7 | -373.3 | -271.3 | -3649.0 | -17.9 | 3 | BULLISH | 4.1 |
| XFOR X4 Pharmaceuticals, Inc. | $320M | -2.8 | -113.1 | -281.1 | -183.5 | -51.6 | 4 | BULLISH | -10.4 |
| LEGN Legend Biotech Corporation | $3.6B | -44.8 | -8.1 | -8.2 | 8.6 | 59.5 | 4 | BULLISH | -29.9 |
| BEAM Beam Therapeutics Inc. | $2.5B | -34.3 | -8.1 | -184.5 | -25036.3 | 158.9 | 4 | BULLISH | 7.7 |
| PVLA Palvella Therapeutics, Inc. | $1.8B | -29.6 | -46.6 | 137.5 | — | — | 3 | BULLISH | 109.4 |
| RARE Ultragenyx Pharmaceutical Inc. | $1.5B | -3.0 | 839.4 | -67.5 | -43.0 | 17.5 | 2 | BULLISH | -51.3 |
| OABIW OmniAb, Inc. | $1.1B | -14.2 | -16.9 | -16.8 | -43.7 | 66.9 | 6 | BULLISH | -14.0 |
| EDIT Editas Medicine, Inc. | $370M | -3.8 | -118.8 | 71.4 | -153.3 | 20.8 | 4 | BULLISH | -9.2 |
| INDP Indaptus Therapeutics, Inc. | $360M | -0.5 | -318.0 | 6437.4 | — | — | 4 | BULLISH | -6.2 |
| GENB Generate Biomedicines, Inc. | $1.6B | -8.8 | -28.2 | -175.0 | -1065.2 | — | 1 | BULLISH | — |
| RXRX Recursion Pharmaceuticals, Inc. | $2.0B | -4.1 | -56.6 | -99.7 | -1708.0 | -14.9 | 4 | BULLISH | -30.9 |
| TGTX TG Therapeutics, Inc. | $8.3B | 18.5 | 100.3 | 73.5 | 3.2 | 76.1 | 6 | BULLISH | 70.4 |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 31.6 | 22.0 | 11.3 | 76.2 | 54.9 | 5 | BULLISH | 67.8 |
| ORKA Oruka Therapeutics, Inc. | $5.3B | -38.3 | -18.2 | -50.3 | — | — | 4 | BULLISH | 246.5 |
| RLAY Relay Therapeutics, Inc. | $4.0B | -12.4 | -36.8 | -2519.7 | -23916.3 | 23.9 | 4 | BULLISH | 166.8 |
| BHVN Biohaven Ltd. | $2.1B | -3.3 | -799.5 | -1083.0 | — | — | 3 | BULLISH | -10.9 |
| ZYME Zymeworks Inc. | $2.0B | -14.4 | -72.3 | -156.9 | -980.8 | -69.8 | 2 | BULLISH | 56.5 |
| ABSI Absci Corporation | $1.6B | -14.4 | -57.7 | -213.1 | -10443.4 | -62.3 | 5 | BULLISH | 164.0 |
| NTLA Intellia Therapeutics, Inc. | $1.6B | -3.8 | -55.4 | -92.1 | -1392.3 | 12.6 | 5 | BULLISH | -10.0 |
| TRAX First Tracks Biotherapeutics Inc | $1.6B | — | — | — | — | — | — | BULLISH | — |
| LBRX LB Pharmaceuticals Inc Common Stock | $1.2B | -13.3 | -25.8 | -768.9 | — | — | 2 | BULLISH | 138.5 |
| ENTX Entera Bio Ltd. | $510M | -9.0 | -138.9 | 314.4 | — | -100.0 | 1 | BULLISH | 33.0 |
| ELVN Enliven Therapeutics, Inc. | $3.0B | -27.0 | -15.3 | -6535.0 | — | — | 3 | BULLISH | 109.2 |
| NAUT Nautilus Biotechnolgy, Inc. | $410M | -6.8 | -41.0 | -89.2 | -6682.1 | — | 2 | BULLISH | 137.8 |
| COGT Cogent Biosciences, Inc. | $5.4B | -13.9 | -109.7 | 1964.0 | — | — | 3 | BULLISH | 99.0 |
| ADPT Adaptive Biotechnologies Corporation | $4.1B | -69.4 | -39.6 | -14.1 | -55.6 | 50.1 | 5 | BULLISH | 65.7 |
| PRTA Prothena Corporation plc | $420M | -10.9 | -14.4 | -871.5 | -1839.9 | 427.3 | 5 | BULLISH | -12.2 |
| KOD Kodiak Sciences Inc. | $5.5B | -23.0 | -368.4 | -630.1 | — | — | 1 | BULLISH | 415.4 |
| XNCR Xencor, Inc. | $1.9B | -13.6 | -29.1 | -152.4 | -42.4 | -36.1 | 2 | BULLISH | 110.2 |
| SRPT Sarepta Therapeutics, Inc. | $1.9B | -13.2 | -9.5 | -6.3 | -1.2 | -20.4 | 4 | BULLISH | -17.8 |
| XERS Xeris Biopharma Holdings, Inc. | $1.9B | -109.5 | 118.2 | 18.3 | -33.8 | 36.3 | 6 | BULLISH | 14.3 |
| SPTX Seaport Therapeutics, Inc. Common Stock | $1.1B | — | — | — | — | — | — | BULLISH | — |
| SLN Silence Therapeutics plc | $930M | -5.2 | -90.4 | 157.8 | — | -97.6 | 1 | BULLISH | 176.1 |
| VCEL Vericel Corporation | $2.2B | 86.1 | 7.2 | 5.9 | 2.8 | 23.0 | 7 | BULLISH | 12.7 |
| NBTX Nanobiotix S.A. | $1.5B | -27.6 | 104.2 | 62.0 | -626.0 | 49.1 | 4 | BULLISH | 125.3 |
| MLTX MoonLake Immunotherapeutics | $1.0B | -3.2 | -67.4 | 2902.7 | — | — | 1 | BULLISH | 22.2 |
| STOK Stoke Therapeutics, Inc. | $1.6B | -7.8 | -61.1 | -318.5 | -660.8 | -86.2 | 2 | BULLISH | -20.0 |
| PHAR Pharming Group N.V. | $710M | 82.6 | 3.6 | 3.2 | 1.8 | 7.8 | 7 | BULLISH | -8.0 |
| CCCC C4 Therapeutics, Inc. | $380M | -3.4 | -48.1 | -175.0 | -355.9 | 2.3 | 4 | BULLISH | 28.3 |
| NGNE Neurogene Inc. | $370M | -5.5 | -45.3 | -111469.0 | — | — | 2 | BULLISH | -5.1 |
| FENC Fennec Pharmaceuticals Inc. | $350M | -82.6 | -18.6 | -76.2 | 11.0 | 77.8 | 6 | BULLISH | 23.2 |
| PBYI Puma Biotechnology, Inc. | $570M | 19.9 | 22.0 | 52.8 | 14.5 | -2.9 | 6 | BULLISH | 101.5 |
| AKBLF ALK-Abelló A/S | $7.4B | 39.9 | 21.2 | 23.9 | 18.9 | 16.4 | 8 | BULLISH | 12.8 |
| ERAS Erasca, Inc. | $5.0B | -15.6 | -78.2 | -87.5 | — | — | 2 | BULLISH | 532.6 |
| IMCR Immunocore Holdings plc | $1.6B | -179.1 | -2.3 | -472.0 | -0.7 | 13.4 | 4 | BULLISH | -2.5 |
| JANX Janux Therapeutics, Inc. | $1.0B | -10.8 | -10.7 | 516.9 | -214.0 | 7162.0 | 4 | BULLISH | -34.0 |
| PHVS Pharvaris N.V. | $2.2B | -10.8 | -70.7 | 860.9 | — | — | 4 | BULLISH | 43.8 |
| ZBIO Zenas BioPharma, Inc. | $1.8B | -3.0 | -199.0 | 5842.1 | -11145.6 | -93.3 | 2 | BULLISH | -9.5 |
| VOR Vor Biopharma Inc. | $990M | 0.1 | -73.6 | 22.2 | — | — | 3 | BULLISH | -26.6 |
| DRUG Bright Minds Biosciences Inc. | $520M | -26.7 | -13.7 | -105758.3 | — | — | 3 | BULLISH | -5.9 |
| BRVE Braveheart Bio, Inc. | $1.5B | — | — | — | — | — | — | BULLISH | — |
| DMRA Damora Therapeutics, Inc. | $1.3B | — | — | — | — | — | — | BULLISH | — |
| PTCHF PureTech Health plc | $390M | 156.7 | 0.2 | 50.8 | 1890.6 | 7.7 | 4 | BULLISH | -5.4 |
| TYRA Tyra Biosciences, Inc. | $1.2B | -8.9 | -45.3 | -2390.9 | — | — | 2 | BULLISH | 46.6 |
| ARVN Arvinas, Inc. | $470M | 39.5 | 1.6 | -519.3 | 67.8 | -15.0 | 4 | BULLISH | -21.2 |
| KURA Kura Oncology, Inc. | $850M | -3.1 | -167.7 | 56.3 | -327.3 | -7.3 | 1 | BULLISH | -2.9 |
| RZLT Rezolute, Inc. | $370M | -5.5 | -59.0 | 1060.6 | — | — | 2 | BULLISH | -55.2 |
| OBIO Orchestra BioMed Holdings, Inc. | $340M | -6.0 | -397.3 | 468.3 | -26994.3 | 986.1 | 4 | BULLISH | 51.6 |
| DYN Dyne Therapeutics, Inc. | $2.9B | -5.0 | -81.6 | 240.4 | — | — | 2 | BULLISH | -29.8 |
| DNA Ginkgo Bioworks Holdings, Inc. | $670M | -2.7 | -56.3 | -44.0 | -231.7 | -51.5 | 2 | BULLISH | -0.4 |
| ACAD Acadia Pharmaceuticals Inc. | $3.4B | 9.0 | 35.7 | 63.9 | 10.2 | 11.8 | 5 | LEAN BULL | -11.6 |
| QURE uniQure N.V. | $1.6B | -6.1 | -157.6 | 37.9 | -1387.8 | 30.2 | 4 | LEAN BULL | -63.2 |
| IOVA Iovance Biotherapeutics, Inc. | $6.4B | -20.1 | -40.4 | -49.1 | -47.6 | 34.5 | 6 | LEAN BULL | 541.1 |
| PTGX Protagonist Therapeutics, Inc. | $9.0B | 115.9 | 11.0 | 84.1 | 76.3 | 34.8 | 7 | LEAN BULL | 88.9 |
| MIRM Mirum Pharmaceuticals, Inc. | $5.2B | -5.9 | -703.0 | -27.3 | -38.1 | 44.0 | 3 | LEAN BULL | 19.9 |
| DFTX Definium Therapeutics, Inc. | $4.8B | -11.0 | -25.7 | 82.4 | — | — | 2 | LEAN BULL | — |
| VERA Vera Therapeutics, Inc. | $2.0B | -5.2 | -91.8 | 2030.6 | — | — | 1 | LEAN BULL | 1.7 |
| BCRX BioCryst Pharmaceuticals, Inc. | $1.9B | -5.7 | 87.8 | 62.3 | 35.9 | 68.7 | 5 | LEAN BULL | 14.5 |
| CMPS COMPASS Pathways plc | $1.6B | -2.2 | -319.1 | 48.8 | — | — | 2 | LEAN BULL | 87.8 |
| OVID Ovid Therapeutics Inc. | $420M | -5.1 | -26.0 | -43.7 | -2047.6 | -76.2 | 3 | LEAN BULL | 53.1 |
| ABCL AbCellera Biologics Inc. | $3.8B | -24.7 | -17.3 | -36.2 | -1368.6 | 101.3 | 4 | LEAN BULL | 136.4 |
| ANAB AnaptysBio, Inc. | $1.5B | 7.4 | -1146.3 | 466.0 | 668.9 | 92.9 | 5 | LEAN BULL | 109.4 |
| TWST Twist Bioscience Corporation | $9.2B | -77.7 | -29.6 | -29.2 | -29.6 | 19.2 | 2 | LEAN BULL | 407.5 |
| PRAX Praxis Precision Medicines, Inc. | $7.1B | -21.7 | -38.9 | -51.2 | — | -100.0 | 4 | LEAN BULL | 53.5 |
| INVA Innoviva, Inc. | $1.5B | 4.3 | 36.7 | 15.0 | -69.8 | 19.8 | 7 | LEAN BULL | 19.2 |
| YDES YD Bio Limited Ordinary Shares | $350M | — | — | — | — | — | — | LEAN BULL | -62.1 |
| ZURA Zura Bio Limited | $320M | -3.8 | -65.4 | 806.5 | — | — | 2 | LEAN BULL | 10.7 |
| ACRS Aclaris Therapeutics, Inc. | $550M | -6.6 | -59.1 | -206.5 | -1320.1 | -51.0 | 3 | LEAN BULL | 69.2 |
| WVE Wave Life Sciences Ltd. | $630M | -3.4 | -80.0 | -1243.7 | -470.5 | -35.1 | 2 | LEAN BULL | -52.2 |
| EWTX Edgewise Therapeutics, Inc. | $4.2B | -21.6 | -38.0 | 1912.5 | — | — | 1 | LEAN BULL | 152.6 |
| TXG 10x Genomics, Inc. | $9.3B | -141.7 | -9.4 | -19.8 | -11.9 | -4.3 | 5 | LEAN BULL | 515.2 |
| CYDY CytoDyn Inc. | $380M | -4.9 | 57.8 | 24.6 | — | 100.0 | 4 | NEUTRAL | -16.7 |
| CGEM Cullinan Therapeutics, Inc. | $880M | -4.5 | -50.3 | 1635.6 | — | — | 1 | NEUTRAL | 93.0 |
| BCHMF Bachem Holding AG | $6.8B | 42.2 | 10.6 | 8.2 | 15.4 | 4.3 | 3 | NEUTRAL | 24.7 |
| XENE Xenon Pharmaceuticals Inc. | $3.4B | -7.6 | -43.6 | -109.7 | — | -100.0 | 3 | NEUTRAL | -13.2 |
| PBLS Parabilis Medicines, Inc. | $3.0B | — | — | — | — | — | — | NEUTRAL | — |
| STTK Shattuck Labs, Inc. | $550M | -11.2 | -39.2 | -29.3 | — | -66.6 | 4 | NEUTRAL | 182.0 |
| LYCA Lycia Therapeutics Inc. | $1.6B | — | — | — | — | — | — | N/A | — |
| ODTX Odyssey Therapeutics, Inc. | $940M | — | — | — | — | — | — | NEUTRAL | — |
| JBIO Jade Biosciences, Inc. | $930M | -5.2 | -47.8 | 629.9 | — | — | 3 | NEUTRAL | 43.2 |
| SVRA Savara Inc. | $870M | -8.6 | -105.5 | -15438.9 | — | — | 2 | NEUTRAL | 14.6 |
| ALMS Alumis Inc. | $880M | -1.9 | -93.6 | 2645.2 | -8557.2 | -63.1 | 2 | NEUTRAL | 48.2 |
| CRSP CRISPR Therapeutics AG | $4.8B | -11.1 | -26.1 | -253.2 | -895.3 | -62.7 | 3 | NEUTRAL | -17.7 |
| ZLAB Zai Lab Limited | $2.7B | -13.3 | -26.9 | -85.4 | -47.8 | 5.1 | 3 | NEUTRAL | -12.5 |
| IONS Ionis Pharmaceuticals, Inc. | $7.1B | -12.7 | -105.4 | -58.5 | -42.8 | -7.4 | 3 | NEUTRAL | -38.5 |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.2B | -29.6 | -200.0 | 144.2 | -69.2 | 53.5 | 4 | NEUTRAL | -17.6 |
| SRRK Scholar Rock Holding Corporation | $5.0B | -13.0 | -167.8 | 931.3 | — | — | 2 | NEUTRAL | 41.8 |
| GLPGF Lakefront Biotherapeutics | $2.1B | 3.9 | 20.2 | 39.4 | 17.4 | 259.3 | 5 | LEAN BEAR | -4.5 |
| CGON CG Oncology Inc. | $5.5B | -23.7 | -26.4 | -2066.1 | -6832.8 | 1030.3 | 3 | LEAN BEAR | 44.4 |
| ENTA Enanta Pharmaceuticals, Inc. | $340M | -4.8 | -70.1 | 141.5 | -135.8 | 0.7 | 4 | LEAN BEAR | 10.0 |
| GYRE Gyre Therapeutics, Inc. | $620M | -34.7 | -15.6 | -22.3 | -36.4 | 16.8 | 3 | LEAN BEAR | -11.6 |
| TRVI Trevi Therapeutics, Inc. | $1.8B | -39.8 | -19.7 | -1451.7 | — | — | 3 | LEAN BEAR | 28.8 |
| AURA Aura Biosciences, Inc. | $650M | -3.6 | -53.5 | -1360.0 | — | — | 4 | LEAN BEAR | 4.9 |
| TTRX Turn Therapeutics Inc. | $310M | -37.9 | -952.4 | 115.0 | — | — | 2 | LEAN BEAR | 123.7 |
| DNTH Dianthus Therapeutics, Inc. | $4.3B | -621.3 | -4.1 | -60.1 | -6598.6 | -60.8 | 3 | LEAN BEAR | 145.6 |
| SLDB Solid Biosciences Inc. | $630M | -3.4 | -65.5 | -1012.6 | — | — | 3 | LEAN BEAR | 9.8 |
| HNGZY Hangzhou Tigermed Consulting Co., Ltd | $6.9B | 603.3 | 0.5 | 1.6 | -24.2 | 12.0 | 6 | LEAN BEAR | 11.2 |
| SHJBF Shanghai Junshi Biosciences Co., Ltd. | $4.8B | -70.9 | -7.1 | -6.3 | 4.4 | 29.7 | 5 | LEAN BEAR | -20.8 |
| PTCT PTC Therapeutics, Inc. | $5.1B | -127.6 | 20.6 | -5.4 | 23.2 | -42.8 | 2 | LEAN BEAR | -6.0 |
| CELC Celcuity Inc. | $3.2B | -16.1 | -1433.7 | 1325.2 | — | — | 3 | LEAN BEAR | -10.4 |
| TSHA Taysha Gene Therapies, Inc. | $1.3B | -10.0 | -47.1 | 961.0 | — | -32.3 | 3 | LEAN BEAR | -13.1 |
| MNKD MannKind Corporation | $1.0B | -24.2 | 71.4 | 4.0 | -17.4 | 30.5 | 2 | LEAN BEAR | -36.7 |
| KARD Kardigan, Inc. | $1.1B | — | — | — | — | — | — | LEAN BEAR | — |
| FDMT 4D Molecular Therapeutics, Inc. | $600M | -4.6 | -43.3 | -182.0 | -1929.0 | 278712.1 | 4 | LEAN BEAR | 5.4 |
| FGHQF Frontage Holdings Corporation | $360M | 36.5 | 3.1 | 3.0 | 4.6 | 9.8 | 7 | LEAN BEAR | 16.8 |
| GWIN Glorywin Entertainment Group, Inc. | $360M | -26081.4 | 11.7 | 5.1 | — | — | 1 | LEAN BEAR | 229.5 |
| NURPF Neuren Pharmaceuticals Limited | $1.8B | 119.7 | 6.2 | 22.4 | 14.6 | -68.5 | 5 | LEAN BEAR | 20.8 |
| IMNM Immunome, Inc. | $2.1B | -7.3 | -64.0 | -2208.4 | — | -100.0 | 4 | LEAN BEAR | 13.0 |
| ADRX ADARx Pharmaceuticals, Inc. | $1.9B | — | — | — | — | — | — | LEAN BEAR | — |
| ANNX Annexon, Inc. | $610M | -3.4 | -105.3 | -11323.3 | — | — | 2 | BEARISH | 14.1 |
| GLUE Monte Rosa Therapeutics, Inc. | $920M | -4.9 | -42.7 | 149.9 | -483.9 | -83.9 | 3 | BEARISH | -11.9 |
| SANA Sana Biotechnology, Inc. | $700M | -3.4 | -152.9 | -242.3 | — | — | 3 | BEARISH | -49.9 |
| OCS Oculis Holding AG | $490M | -4.7 | -44.0 | -31.0 | — | -6.9 | 3 | BEARISH | -63.0 |
| RLMD Relmada Therapeutics, Inc. | $350M | -3.6 | -55.7 | 460.5 | — | — | 3 | BEARISH | 43.8 |
| ALLO Allogene Therapeutics, Inc. | $430M | -1.9 | -42.4 | -81.9 | -919.8 | — | 5 | BEARISH | 5.7 |
| AAPG Ascentage Pharma Group International | $1.4B | -6.3 | -236.8 | -144.8 | -270.2 | 170.9 | 3 | BEARISH | -56.5 |
| SNBIF SanBio Company Limited | $1.3B | -19.8 | -55.8 | -2935.2 | — | — | 3 | BEARISH | 0.0 |
| BPMUF Basilea Pharmaceutica AG | $960M | 17.2 | 39.5 | 75.9 | 23.5 | 4.5 | 7 | BEARISH | 27.1 |
| HRMY Harmony Biosciences Holdings, Inc. | $2.1B | 12.2 | 20.5 | 35.7 | 28.9 | 24.3 | 5 | BEARISH | 27.9 |
| CLYM Climb Bio, Inc. | $590M | -11.9 | -27.1 | -88.6 | — | — | 2 | BEARISH | 381.9 |
| MNPR Monopar Therapeutics Inc. | $470M | -30.8 | -19.5 | 523.8 | — | — | 2 | BEARISH | -9.7 |
| MEOBF Mesoblast Limited | $2.0B | -29.9 | -9.9 | -6.4 | -23.4 | 613.8 | 5 | BEARISH | -21.4 |
| PCVX Vaxcyte, Inc. | $9.5B | -8.0 | -36.5 | -66.4 | — | — | 0 | BEARISH | 37.9 |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.2B | -26.5 | -64.8 | 65.7 | -258.2 | 12.2 | 4 | BEARISH | 52.5 |
| AMLX Amylyx Pharmaceuticals, Inc. | $3.4B | -19.8 | -74.7 | 2020.5 | — | 100.0 | 5 | BEARISH | 97.3 |
| MBX MBX Biosciences, Inc. Common Stock | $2.3B | -22.1 | -33.2 | 1634.0 | — | — | 2 | BEARISH | 210.6 |
| MLYS Mineralys Therapeutics, Inc. | $1.8B | -5.0 | -80.9 | 2274.6 | — | — | 2 | BEARISH | -47.3 |
| IMTX Immatics N.V. | $1.1B | -4.1 | -47.8 | -858.3 | -683.4 | -68.0 | 2 | BEARISH | -30.5 |
| AKTS Aktis Oncology, Inc. | $850M | -15.9 | -29.9 | 276.4 | -713.5 | -36.1 | 5 | BEARISH | 365552.2 |
| ATTO Attovia Therapeutics, Inc. | $630M | -17.0 | -294.4 | -1137.2 | -4597.1 | -50.5 | 4 | BEARISH | 313.6 |
| OLMA Olema Pharmaceuticals, Inc. | $560M | -3.5 | -52.7 | 585.3 | — | — | 2 | BEARISH | -14.8 |
| BNTC Benitec Biopharma Inc. | $300M | -8.8 | -33.2 | 1840.8 | — | — | 3 | BEARISH | -34.9 |
| TARS Tarsus Pharmaceuticals, Inc. | $3.2B | -66.0 | -13.7 | 268.1 | -10.7 | 105.2 | 5 | BEARISH | 5.7 |
| CSPHF CStone Pharmaceuticals | $1.4B | -15.0 | -51.4 | -340.2 | -123.0 | 135.6 | 5 | BEARISH | -15.4 |
| DRTSW Alpha Tau Medical Ltd. | $1.2B | -12.8 | -141.7 | -17.1 | — | — | 3 | BEARISH | 820.5 |
| GHRS GH Research PLC | $1.2B | -20.4 | -18.8 | 2015.5 | — | — | 2 | BEARISH | 44.6 |
| DSGN Design Therapeutics, Inc. | $640M | -9.2 | -34.1 | 1787.8 | — | — | 1 | BEARISH | 59.0 |
| HNSBF Hansa Biopharma AB (publ) | $330M | -4.9 | 159.8 | 1182.7 | -541.7 | -3.7 | 2 | BEARISH | -28.2 |
| IDRSF Idorsia Ltd | $1.4B | -3.5 | 27.1 | -344.5 | -203.1 | -8.1 | 1 | BEARISH | 19.6 |
| VBIZF Viva Biotech Holdings | $400M | 13.9 | 4.5 | 4.2 | 8.0 | 2.9 | 7 | BEARISH | -35.1 |
| DNLI Denali Therapeutics Inc. | $2.9B | -6.7 | -54.9 | -281.7 | -3539.2 | — | 3 | BEARISH | 19.0 |
| CASBF CanSino Biologics Inc. | $1.4B | 399.2 | 0.8 | -1.2 | 11.0 | 32.5 | 7 | BEARISH | -39.1 |
| CRVS Corvus Pharmaceuticals, Inc. | $890M | -16.2 | -35.4 | -415.6 | — | — | 4 | BEARISH | 33.8 |
| CLDX Celldex Therapeutics, Inc. | $2.3B | -6.7 | -43.9 | -13685.9 | -334104.5 | -98.1 | 1 | BEARISH | 8.4 |
| NKTR Nektar Therapeutics | $1.1B | -5.7 | -35.8 | -29.2 | -401.0 | -27.2 | 3 | BEARISH | -38.4 |
| RGNX REGENXBIO Inc. | $440M | -1.9 | -137.6 | -368.4 | 21.0 | 12.0 | 2 | BEARISH | -46.8 |
| BLSM BlossomHill Therapeutics, Inc. | $430M | — | — | — | — | — | — | BEARISH | — |
| TECX Tectonic Therapeutic, Inc. | $390M | -4.5 | -33.8 | -6371.3 | — | — | 1 | BEARISH | 10.4 |
| TNGX Tango Therapeutics, Inc. | $3.9B | -26.7 | -21.3 | -253.2 | — | 121.5 | 3 | BEARISH | 186.1 |
| TLX Telix Pharmaceuticals Limited | $3.1B | 96.4 | 6.8 | -0.5 | 8.0 | -7.7 | 3 | BEARISH | -15.4 |
| PPTDF PeptiDream Inc. | $870M | -39.5 | -7.1 | -9.6 | -25.7 | 47.8 | 4 | BEARISH | -38.7 |
| IMVT Immunovant, Inc. | $5.9B | -10.4 | -80.1 | 707.5 | -2159.6 | — | 2 | BEARISH | 37.3 |
| ANRO Alto Neuroscience, Inc. | $860M | -9.3 | -49.2 | -201.4 | — | — | 3 | BEARISH | 90.5 |
| ABUS Arbutus Biopharma Corp | $830M | 5.4 | 89.6 | 86.7 | -507.2 | 1078.8 | 4 | BEARISH | -3.4 |
| GNNSF Genscript Biotech Corporation | $9.6B | -15.7 | -15.4 | 2.9 | -32.0 | 53.1 | 4 | BEARISH | 103.7 |
| NUVB Nuvation Bio Inc. | $1.6B | -10.4 | -47.8 | 70.2 | -198.3 | 1083.6 | 4 | BEARISH | -8.7 |
| AUTL Autolus Therapeutics plc | $410M | -1.5 | -132.9 | 451.5 | -85.6 | 292.0 | 3 | BEARISH | -1.2 |
| OCUL Ocular Therapeutix, Inc. | $1.4B | -5.0 | -73.0 | -31671.3 | -584.5 | -8.1 | 3 | BEARISH | -36.9 |
| OMER Omeros Corporation | $1.2B | 9.2 | -89.2 | 71.8 | 46.4 | — | 5 | BEARISH | 131.9 |
| AVBP ArriVent BioPharma, Inc. | $1.0B | -4.2 | -53.1 | 2345.1 | — | — | 3 | BEARISH | -19.3 |
| EPRX Eupraxia Pharmaceuticals Inc. | $450M | -7.1 | -68.6 | 8742.2 | — | — | 3 | BEARISH | 33.5 |
| IBRX ImmunityBio, Inc. | $8.7B | -8.8 | 122.7 | 33.7 | -449.6 | 192.9 | 4 | BEARISH | 231.9 |
| CAMRF Camurus AB | $3.7B | 58.8 | 15.8 | 89.3 | 34.3 | -0.2 | 6 | BEARISH | -10.3 |
| ORIC ORIC Pharmaceuticals, Inc. | $1.4B | -6.7 | -39.8 | -102.9 | — | — | 3 | BEARISH | -30.6 |
| RAPP Rapport Therapeutics, Inc. Common Stock | $1.2B | -7.4 | -40.0 | 3981.5 | — | — | 4 | BEARISH | -15.0 |
| DRTS Alpha Tau Medical Ltd | $1.2B | -12.8 | -141.7 | -17.1 | — | — | 3 | BEARISH | 220.9 |
| MGTX MeiraGTx Holdings plc | $880M | 12.6 | 72.3 | 96.7 | 50.0 | 948.3 | 7 | BEARISH | 9.9 |
| RCUS Arcus Biosciences, Inc. | $2.3B | -4.6 | -89.2 | 309.6 | -222.0 | -55.3 | 0 | BEARISH | -0.9 |
| NAMS NewAmsterdam Pharma Company N.V. | $2.3B | -9.5 | -36.8 | 8216.2 | -1732.9 | -88.9 | 2 | BEARISH | -41.5 |
| AVLN Avalyn Pharma Inc. Common Stock | $1.1B | — | — | — | — | — | — | BEARISH | — |
| APMD Apnimed, Inc. | $790M | — | — | — | — | — | — | BEARISH | — |
| CBIO Crescent Biopharma, Inc. | $480M | -1.8 | -107.7 | 1928.6 | — | — | 5 | BEARISH | 3.9 |
| KYTX Kyverna Therapeutics, Inc. | $330M | -2.0 | -87.2 | 14267.8 | — | — | 2 | BEARISH | -24.6 |
| KRYS Krystal Biotech, Inc. | $9.2B | 38.4 | 20.1 | 40.4 | 45.9 | 22.6 | 7 | BEARISH | 69.2 |
| GERN Geron Corporation | $720M | -9.6 | -29.2 | -74.1 | -29.0 | 24.4 | 2 | BEARISH | -24.3 |
| ZVRA Zevra Therapeutics, Inc. | $580M | 10.6 | 34.8 | -1356.4 | 22.1 | 119.4 | 6 | BEARISH | -7.0 |
| PHAT Phathom Pharmaceuticals, Inc. | $460M | -4.9 | 26.4 | 8.9 | -23.7 | 110.2 | 4 | BEARISH | -54.5 |
| FTH Faeth Therapeutics, Inc. | $440M | — | — | — | — | — | — | BEARISH | — |
| TVTX Travere Therapeutics, Inc. | $4.7B | -111.7 | -151.8 | -21.0 | -20.5 | 77.1 | 6 | BEARISH | 70.8 |
| NVAX Novavax, Inc. | $1.6B | -6.7 | 323.7 | 29.2 | -94.2 | -61.6 | 2 | BEARISH | 18.6 |
| NWPHF Newron Pharmaceuticals S.p.A. | $410M | -6.6 | 83.9 | -32.1 | -513.4 | — | 1 | BEARISH | — |
| SNDX Syndax Pharmaceuticals, Inc. | $1.2B | -5.5 | -255.9 | -270.9 | -67.8 | 222.3 | 4 | BEARISH | 9.2 |
| CTMX CytomX Therapeutics, Inc. | $510M | -5.2 | -37.8 | 305.9 | -1457.4 | -87.0 | 2 | BEARISH | -29.8 |
| ASMB Assembly Biosciences, Inc. | $400M | 37.2 | -0.0 | 56.2 | -28.8 | 125.1 | 4 | BEARISH | -31.0 |
| MPLT MapLight Therapeutics, Inc. | $340M | -1.5 | -57.5 | -366.6 | — | — | 2 | BEARISH | -56.5 |
| IDYA IDEAYA Biosciences, Inc. | $3.4B | -17.7 | -16.2 | -42.9 | -1269.6 | 3244.7 | 4 | BEARISH | 4.9 |
| SLS SELLAS Life Sciences Group, Inc. | $2.3B | -48.9 | -39.6 | 55646.0 | — | — | 4 | BEARISH | 435.1 |
| PGEN Precigen, Inc. | $2.2B | -5.3 | -4640.4 | -30.1 | 36.5 | 1875.0 | 5 | BEARISH | 41.4 |
| ASCLF Ascletis Pharma Inc. | $770M | -7.8 | -28.4 | -7144.0 | — | -60.6 | 2 | BEARISH | -40.0 |
| ACHV Achieve Life Sciences, Inc. | $670M | -4.3 | -845.0 | 24.6 | — | — | 2 | BEARISH | 46.4 |
| NVCT Nuvectis Pharma, Inc. | $650M | -14.0 | -214.6 | 174.4 | — | — | 1 | BEARISH | 180.3 |
| BLTE Belite Bio, Inc | $5.9B | -53.3 | -20.8 | -11.5 | — | — | 3 | BEARISH | 58.5 |
| IMMX Immix Biopharma, Inc. | $680M | -9.1 | -34.2 | 1509.2 | — | — | 4 | BEARISH | 139.8 |
| LXRX Lexicon Pharmaceuticals, Inc. | $630M | -9.7 | -40.2 | -99.7 | -4591.8 | -29.0 | 3 | BEARISH | 28.4 |
| CADL Candel Therapeutics, Inc. | $610M | -6.0 | -81.8 | 219.4 | — | — | 2 | BEARISH | 60.6 |
| MDXG MiMedx Group, Inc. | $570M | 97.9 | 2.9 | 5.8 | -23.1 | -2.4 | 6 | BEARISH | -41.3 |
| AVIR Atea Pharmaceuticals, Inc. | $320M | -2.0 | -58.1 | 974.6 | — | — | 3 | BEARISH | 31.4 |
| CYTK Cytokinetics, Incorporated | $8.5B | -8.4 | 329.8 | 811.2 | -622.8 | -17.2 | 2 | BEARISH | 1.8 |
| HBMHF HBM Holdings Limited | $1.3B | 12.7 | 24.1 | 53.0 | 53.0 | 54.6 | 4 | BEARISH | -38.1 |
| GPCR Structure Therapeutics Inc. | $1.2B | -7.0 | -20.2 | -1134.3 | — | — | 3 | BEARISH | -25.0 |
| ARDX Ardelyx, Inc. | $770M | -13.5 | -38.6 | -22.7 | -13.8 | 16.8 | 4 | BEARISH | -39.2 |
| SLBT SL Science Holding Ltd | $640M | — | — | — | — | — | — | BEARISH | — |
| PROK ProKidney Corp. | $470M | -2.6 | 9.2 | 13.2 | -18948.0 | 55.2 | 1 | BEARISH | -52.8 |
| INBX Inhibrx Biosciences Inc. | $1.4B | -8.0 | -1773.6 | 55.8 | — | -100.0 | 4 | BEARISH | 24.5 |
| URGN UroGen Pharma Ltd. | $1.7B | -17.0 | 86.5 | 119.0 | -19.8 | 169.5 | 2 | BEARISH | 61.9 |
| MDCLF MedinCell S.A. | $1.1B | -29.2 | 472.2 | 81.6 | -152.1 | -14.8 | 3 | BEARISH | 333.5 |
| ANL Adlai Nortye Ltd. | $560M | -5.2 | -22.4 | -317.5 | -36.3 | 223.4 | 4 | BEARISH | 575.5 |
| GNFTF Genfit S.A. | $470M | -5.6 | -5084.0 | -322.7 | -124.0 | 27.5 | 3 | BEARISH | 153.5 |
| ARTV Artiva Biotherapeutics, Inc. | $300M | -1.3 | -36.6 | -954.6 | — | — | 3 | BEARISH | -15.1 |
| AXSM Axsome Therapeutics, Inc. | $7.6B | -38.4 | -245.1 | 859.1 | -23.5 | 56.9 | 5 | BEARISH | 6.6 |
| REGMF RemeGen Co., Ltd. | $5.6B | 9.3 | 108.3 | 139.6 | 83.4 | 283.6 | 7 | BEARISH | -7.7 |
| VKTX Viking Therapeutics, Inc. | $3.1B | -5.3 | -88.9 | 495.6 | — | — | 1 | BEARISH | -29.4 |
| GENSF Genus plc | $1.8B | 5.4 | 45.4 | 9.0 | 80.4 | -3.8 | 5 | BEARISH | -19.4 |
| AGMB AgomAb Therapeutics N.V. American Depositary Shares | $450M | — | — | — | — | — | — | BEARISH | — |
| AVCTF Avacta Group Plc | $420M | -6.7 | -2083.2 | -753.6 | -33970.3 | -99.7 | 5 | BEARISH | -18.7 |
| ALT Altimmune, Inc. | $410M | -2.6 | -28.9 | -43.1 | — | 55.0 | 4 | BEARISH | -47.0 |
| AVTX Avalo Therapeutics, Inc. | $370M | -1.4 | -36.3 | -148.4 | — | -86.6 | 4 | BEARISH | -60.4 |
| CAPR Capricor Therapeutics, Inc. | $340M | -2.5 | -73.7 | -107.5 | — | -100.0 | 3 | BEARISH | 0.8 |
| TRSBF 3SBio Inc. | $4.3B | 3.5 | 37.1 | 80.3 | 25.3 | 93.8 | 7 | BEARISH | -51.7 |
| BRCTF BioArctic AB | $2.6B | 269.1 | 5.2 | 77.4 | -4.5 | -46.1 | 3 | BEARISH | -8.6 |
| ZLDPF Zealand Pharma A/S | $2.4B | 5.9 | 16.3 | 57.2 | 87.2 | -49.2 | 3 | BEARISH | -54.1 |
| INCPF InnoCare Pharma Limited | $2.4B | 19.1 | 12.6 | 45.8 | 23.1 | 108.5 | 4 | BEARISH | -50.9 |
| PHMMF Pharma Mar, S.A. | $1.6B | 21.0 | 24.9 | 35.9 | -2.0 | 15.5 | 7 | BEARISH | -16.4 |
| BCAX Bicara Therapeutics Inc. Common Stock | $1.1B | -3.0 | -41.0 | 583.9 | — | — | 2 | BEARISH | -42.6 |
| IVEVF Inventiva S.A. | $750M | -6.2 | -988.4 | -371.6 | -347346.6 | -99.7 | 3 | BEARISH | -22.8 |
| INRLF Valneva SE | $640M | -2.8 | -118.0 | -54.8 | -89.3 | -27.2 | 1 | BEARISH | -44.9 |
| SPRY ARS Pharmaceuticals, Inc. | $400M | -1.6 | -210.3 | -424.3 | -185.2 | 4.1 | 2 | BEARISH | -61.8 |
| EIKN Eikon Therapeutics, Inc. Common Stock | $390M | — | — | — | — | — | — | BEARISH | — |
| DMTRF 3-D Matrix, Ltd. | $310M | 12.4 | 75.0 | 31.1 | 9.4 | 57.0 | 6 | BEARISH | 61.3 |
| VIR Vir Biotechnology, Inc. | $1.8B | -6.4 | -26.1 | -38.8 | 33.5 | 1495.9 | 5 | BULLISH | 92.7 |
| HCSG Healthcare Services Group, Inc. | $1.7B | 15.9 | 20.4 | 27.0 | 5.2 | 4.0 | 7 | BULLISH | 27.0 |
| AMN AMN Healthcare Services, Inc. | $1.9B | 17.3 | 15.6 | 8.9 | 3.1 | 24.0 | 8 | BULLISH | 122.4 |
| ARDT Ardent Health Inc. | $1.7B | 21.6 | 6.0 | 13.5 | 1.0 | 3.3 | 5 | BULLISH | -21.1 |
| XRAY DENTSPLY SIRONA Inc. | $1.9B | -3.4 | -33.0 | 9.9 | 4.1 | -0.8 | 5 | BULLISH | -26.8 |
| SAEYY Redcare Pharmacy N.V. | $1.7B | -37.9 | -8.7 | -1.2 | 0.6 | 20.5 | 2 | BULLISH | -5.2 |
| TGLVY Top Glove Corporation Bhd. | $1.7B | 25.3 | 6.3 | 8.5 | 12.6 | 21.4 | 8 | BULLISH | 56.4 |
| KMTS Kestra Medical Technologies, Ltd. | $1.7B | -11.3 | -73.7 | -113.5 | -142.3 | 191.6 | 3 | BULLISH | 10.3 |
| OMCL Omnicell, Inc. | $1.7B | 42.3 | 3.1 | 3.2 | 7.8 | 8.5 | 9 | BULLISH | 17.7 |
| ATEC Alphatec Holdings, Inc. | $1.7B | -15.8 | -623.1 | -7.6 | -12.1 | 19.5 | 5 | LEAN BULL | -30.9 |
| TSMRF Tsumura & Co. | $1.7B | 9.1 | 9.9 | 6.6 | 13.0 | 10.7 | 4 | LEAN BULL | 0.0 |
| PSNL Personalis, Inc. | $1.7B | -14.6 | -50.3 | -149.3 | -141.7 | -13.3 | 2 | LEAN BULL | 65.3 |
| BFLY Butterfly Network, Inc. | $1.8B | -26.9 | -35.5 | -74.8 | -39.6 | 28.1 | 4 | LEAN BEAR | 255.9 |
| ASTH Astrana Health, Inc. | $1.9B | 44.2 | 5.1 | 4.7 | 2.0 | 58.9 | 5 | LEAN BEAR | 10.9 |
| EXETF Extendicare Inc. | $1.9B | 19.8 | 43.8 | 14.1 | 5.0 | 31.2 | 3 | BEARISH | 70.0 |
| TRLV Trulieve Cannabis Corp. | $1.8B | — | — | — | — | — | — | BEARISH | — |
| SGIPF Sugi Holdings Co.,Ltd. | $1.8B | 15.9 | 10.0 | 11.6 | 2.2 | 46.6 | 7 | BEARISH | 0.9 |
| NVCR Novocure Ltd | $1.7B | -10.7 | -43.2 | -93.1 | -8.5 | 11.0 | 6 | BEARISH | 4.3 |
| CURLF Curaleaf Holdings, Inc. | $1.8B | -61.0 | -4.2 | 0.5 | 3.7 | 2.7 | 7 | BEARISH | -1.5 |
| ADDLF AddLife AB (publ) | $1.9B | 34.7 | 11.3 | 7.0 | 4.9 | 1.1 | 4 | BEARISH | -62.5 |
| ULIHF The United Laboratories International Holdings Limited | $1.9B | 21.1 | 3.3 | 4.4 | 5.6 | -16.6 | 4 | BEARISH | -49.9 |
| VIR Vir Biotechnology, Inc. | $1.8B | -6.4 | -26.1 | -38.8 | 33.5 | 1495.9 | 5 | BULLISH | 92.7 |
| KYMR Kymera Therapeutics, Inc. | $9.1B | -37.5 | -24.2 | -30.7 | -94.2 | 134.8 | 6 | BULLISH | 101.3 |
| CAI Caris Life Sciences, Inc. | $9.1B | 96.5 | 20.1 | 61.1 | -0.2 | 445.5 | 7 | BULLISH | 17.2 |
| HNGE Hinge Health, Inc. | $9.0B | 85.0 | 30.4 | -235.0 | 20.5 | 417.7 | 7 | BULLISH | 131.1 |
| SYRE Spyre Therapeutics, Inc. | $8.3B | -50.5 | -23.0 | 359.8 | — | — | 3 | BULLISH | 306.0 |
| ALKS Alkermes plc | $7.3B | 111.7 | 3.9 | 2.9 | 0.1 | 10.8 | 4 | BULLISH | 52.2 |
| KNSA Kiniksa Pharmaceuticals International, plc | $6.0B | 65.9 | 17.6 | 65.5 | 16.6 | 58.2 | 7 | BULLISH | 134.4 |
| DOCS Doximity, Inc. | $6.0B | 38.1 | 17.2 | 60.2 | 15.5 | 11.2 | 6 | BULLISH | -50.0 |
| MANE Veradermics, Incorporated | $5.8B | — | — | — | — | — | — | BULLISH | — |
| TFX Teleflex Incorporated | $5.8B | -5.9 | -28.8 | 1.3 | 17.9 | -14.5 | 5 | BULLISH | 5.2 |
| BLLN BillionToOne, Inc. | $5.1B | 166.3 | 6.0 | 25.2 | 7.4 | — | 4 | BULLISH | — |
| CON Concentra Group Holdings Parent, Inc. | $5.0B | 26.1 | 48.5 | 66.4 | 10.8 | 14.0 | 9 | BULLISH | 95.8 |
| HTFL Heartflow, Inc. Common Stock | $4.9B | -41.3 | -42.3 | -39.8 | -24.6 | — | 2 | BULLISH | 54.1 |
| IRON Disc Medicine, Inc. | $2.9B | -12.6 | -39.1 | 1672.3 | — | — | 1 | BULLISH | -7.2 |
| NRIX Nurix Therapeutics, Inc. | $2.8B | 10.7 | 44.0 | -1896.6 | 81.7 | 738.8 | 8 | BULLISH | 127.5 |
| FTRE Fortrea Holdings Inc. | $2.2B | -27.4 | -15.3 | 0.6 | -1.9 | -2.1 | 6 | BULLISH | 149.1 |
| AUPH Aurinia Pharmaceuticals Inc. | $2.2B | 7.3 | 66.1 | 127.2 | 45.0 | 19.8 | 7 | BULLISH | 41.2 |
| AGIO Agios Pharmaceuticals, Inc. | $2.2B | -5.4 | -34.3 | -82.5 | -225.1 | 140.6 | 4 | BULLISH | -11.5 |
| ALMR Alamar Biosciences, Inc. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| MRVI Maravai LifeSciences Holdings, Inc. | $2.1B | -15.6 | -32.9 | 24.4 | -24.1 | -3.3 | 5 | BULLISH | 154.5 |
| SGRY Surgery Partners, Inc. | $2.1B | -33.6 | -5.2 | 5.9 | -1.8 | 4.0 | 5 | BULLISH | 1.5 |
| SEPN Septerna Inc | $1.9B | -81.4 | -6.3 | -93.1 | -48.7 | 17878.5 | 5 | BULLISH | 95.6 |
| KLRA Kailera Therapeutics, Inc. | $1.7B | — | — | — | — | — | — | BULLISH | — |
| COAG Hemab Therapeutics Holdings, Inc. Common Stock | $1.6B | — | — | — | — | — | — | BULLISH | — |
| MRCHF H.U. Group Holdings, Inc. | $1.3B | 21.8 | 7.2 | 3.3 | 2.5 | 1.8 | 9 | BULLISH | -7.4 |
| REPL Replimune Group, Inc. | $1.1B | -5.8 | -115.8 | -882.8 | — | — | 3 | BULLISH | 72.1 |
| SIBN SI-BONE, Inc. | $960M | -63.9 | -8.3 | -32.2 | -7.3 | 15.3 | 6 | BULLISH | 39.4 |
| RIGL Rigel Pharmaceuticals, Inc. | $900M | 2.9 | 126.9 | 88.5 | 22.0 | 3.3 | 4 | BULLISH | 71.5 |
| SOLTF Nxera Pharma Co., Ltd. | $770M | -16.2 | -12.0 | -1.7 | -2.6 | 7.5 | 4 | BULLISH | 38.2 |
| CTKB Cytek Biosciences, Inc. | $730M | -9.8 | -23.0 | -40.8 | -25.3 | 5.4 | 3 | BULLISH | 48.0 |
| CRMD CorMedix Inc. | $610M | 3.4 | 54.9 | 57.2 | 25.5 | 280.5 | 5 | BULLISH | -25.8 |
| DMAC DiaMedica Therapeutics Inc. | $470M | -13.6 | -114.6 | 616.3 | — | — | 2 | BULLISH | 42.7 |
| RCEL Avita Medical Inc. | $390M | -11.4 | 211.5 | -292.6 | -35.3 | 1.0 | 4 | BULLISH | 335.4 |
| MOBI Mobia Medical, Inc. Common Stock | $350M | — | — | — | — | — | — | BULLISH | — |
| SGMT Sagimet Biosciences Inc. | $310M | -8.3 | -24.4 | -231.4 | — | — | 3 | BULLISH | 24.9 |
| HQY HealthEquity, Inc. | $8.6B | 36.2 | 11.4 | 9.9 | 18.7 | 7.3 | 8 | BULLISH | 5.4 |
| PACS PACS Group, Inc. | $7.5B | 28.9 | 28.1 | 6.9 | 5.3 | 15.2 | 8 | BULLISH | 289.6 |
| AMRX Amneal Pharmaceuticals, Inc. | $6.5B | 42.6 | -395.8 | 16.0 | 7.2 | 9.3 | 8 | BULLISH | 106.2 |
| BLCO Bausch + Lomb Corporation | $6.2B | -64.2 | -2.7 | 2.8 | -1.0 | 8.8 | 5 | BULLISH | 32.7 |
| GRAL GRAIL Inc. | $5.9B | -16.1 | -16.1 | -24.9 | -246.7 | 23.1 | 5 | BULLISH | 85.7 |
| MMSI Merit Medical Systems, Inc. | $5.6B | 37.8 | 9.2 | 7.3 | 9.3 | 10.2 | 9 | BULLISH | 11.4 |
| WAY Waystar Holding Corp. | $5.5B | 39.8 | 3.8 | 3.8 | 12.8 | 19.2 | 7 | BULLISH | -26.5 |
| LFST LifeStance Health Group, Inc. | $4.9B | 104.3 | 3.4 | 4.1 | 5.4 | 20.4 | 7 | BULLISH | 162.0 |
| ARQT Arcutis Biotherapeutics, Inc. | $3.9B | 142.4 | 15.9 | 34.7 | 11.6 | 76.1 | 7 | BULLISH | 60.1 |
| ATRC AtriCure, Inc. | $3.0B | 289.4 | 2.2 | 2.9 | 5.8 | 13.9 | 8 | BULLISH | 68.4 |
| BVNRY Bavarian Nordic A/S | $2.9B | 13.0 | 12.3 | 7.1 | 36.0 | -5.8 | 7 | BULLISH | 1.6 |
| ONTTF Oxford Nanopore Technologies plc | $2.7B | -18.7 | -25.6 | -36.2 | -41.1 | 14.4 | 4 | BULLISH | 57.6 |
| GNNDY GN Store Nord A/S | $2.4B | -29.3 | -5.4 | 1.6 | -1.0 | -25.4 | 4 | BULLISH | -6.6 |
| BHC Bausch Health Companies Inc. | $2.4B | -2.3 | 86.8 | 12.2 | 9.0 | 10.5 | 5 | BULLISH | 11.9 |
| MD Pediatrix Medical Group, Inc. | $2.4B | 13.7 | 20.4 | 15.9 | 8.2 | 0.5 | 7 | BULLISH | 65.8 |
| BOEUF Bonesupport Holding AB (publ) | $2.1B | 77.2 | 29.2 | 54.1 | 22.6 | 23.4 | 8 | BULLISH | 28.9 |
| LKFT Lakefront Biotherapeutics N.V. | $2.1B | — | — | — | — | — | — | BULLISH | — |
| AMN AMN Healthcare Services, Inc. | $1.9B | 17.3 | 15.6 | 8.9 | 3.1 | 24.0 | 8 | BULLISH | 122.4 |
| HCSG Healthcare Services Group, Inc. | $1.7B | 15.9 | 20.4 | 27.0 | 5.2 | 4.0 | 7 | BULLISH | 27.0 |
| CERT Certara, Inc. | $1.6B | -25.6 | -6.7 | 0.6 | -59.3 | 0.7 | 6 | BULLISH | -8.2 |
| LTGHY Life Healthcare Group Holdings Limited | $1.1B | 2.7 | 68.5 | 10.7 | 6.2 | -3.0 | 4 | BULLISH | 12.6 |
| CBLL CeriBell, Inc. | $1.0B | -15.5 | -43.9 | -263.7 | -68.6 | 69.3 | 3 | BULLISH | 111.2 |
| BVS Bioventus Inc. | $1.0B | 18.1 | 28.0 | 21.3 | 21.8 | 3.1 | 7 | BULLISH | 118.3 |
| SGP SpyGlass Pharma, Inc. Common Stock | $950M | — | — | — | — | — | — | BULLISH | — |
| VSTM Verastem, Inc. | $910M | -4.0 | -471.2 | 6197.3 | -86.5 | 3995.7 | 4 | BULLISH | 12.8 |
| PHR Phreesia, Inc. | $790M | 71.4 | 3.1 | 16.7 | 1.5 | 12.9 | 4 | BULLISH | -47.2 |
| PACB Pacific Biosciences of California, Inc. | $660M | -6.7 | -929.3 | -29.4 | -114.7 | 2.0 | 2 | BULLISH | 35.4 |
| KIDS OrthoPediatrics Corp. | $640M | -21.8 | -9.8 | -4.4 | -8.2 | 16.1 | 6 | BULLISH | 81.6 |
| AONC American Oncology Network, Inc. | $640M | -30.1 | 5.6 | -14.7 | 0.3 | 37.5 | 6 | BULLISH | 135.6 |
| NRC NRC Health | $490M | 76.0 | 248.1 | 10.8 | 12.3 | 3.4 | 6 | BULLISH | 55.5 |
| MASS 908 Devices Inc. | $470M | -13.7 | -25.1 | -103.8 | -74.0 | 4.6 | 5 | BULLISH | 54.5 |
| CV CapsoVision, Inc. | $370M | -11.2 | -226.6 | -73.0 | -205.4 | — | 2 | BULLISH | 45.3 |
| VRDN Viridian Therapeutics, Inc. | $2.5B | -6.9 | -65.7 | 418.2 | -44760.2 | 23220.3 | 4 | BULLISH | 7.7 |
| ADMA ADMA Biologics, Inc. | $2.4B | 15.5 | 41.9 | 35.5 | 30.4 | 8.0 | 5 | BULLISH | -27.7 |
| MAZE Maze Therapeutics, Inc. | $1.7B | -11.5 | -37.3 | -112.3 | — | — | 3 | BULLISH | 2.4 |
| AZTA Azenta, Inc. | $1.6B | -14.7 | -7.7 | -1.4 | 1.5 | 1.5 | 4 | BULLISH | 27.4 |
| ENOV Enovis Corporation | $1.2B | -1.1 | -54.3 | -13.5 | -0.2 | 4.9 | 4 | BULLISH | -33.3 |
| QDEL QuidelOrtho Corporation | $940M | -0.9 | -45.9 | -13.7 | -14.7 | 0.1 | 4 | BULLISH | -52.5 |
| PRME Prime Medicine, Inc. | $670M | -4.7 | -373.3 | -271.3 | -3649.0 | -17.9 | 3 | BULLISH | 4.1 |
| MYGN Myriad Genetics, Inc. | $560M | -5.5 | -32.5 | -19.5 | -22.7 | -3.2 | 4 | BULLISH | -18.1 |
| XFOR X4 Pharmaceuticals, Inc. | $320M | -2.8 | -113.1 | -281.1 | -183.5 | -51.6 | 4 | BULLISH | -10.4 |
| BIO Bio-Rad Laboratories, Inc. | $9.9B | 46.0 | 3.1 | 2.2 | 57.1 | 1.4 | 7 | BULLISH | 14.7 |
| RDNT RadNet, Inc. | $5.5B | -275.4 | -2.1 | 1.8 | 1.2 | 18.9 | 5 | BULLISH | -9.9 |
| SHC Sotera Health Company | $5.2B | 32.3 | 27.8 | 10.6 | 16.7 | 8.1 | 7 | BULLISH | 11.6 |
| PLSE Pulse Biosciences, Inc. | $3.8B | -45.7 | -78.5 | -1410.2 | -5681.3 | — | 3 | BULLISH | 206.7 |
| LEGN Legend Biotech Corporation | $3.6B | -44.8 | -8.1 | -8.2 | 8.6 | 59.5 | 4 | BULLISH | -29.9 |
| BEAM Beam Therapeutics Inc. | $2.5B | -34.3 | -8.1 | -184.5 | -25036.3 | 158.9 | 4 | BULLISH | 7.7 |
| PVLA Palvella Therapeutics, Inc. | $1.8B | -29.6 | -46.6 | 137.5 | — | — | 3 | BULLISH | 109.4 |
| RARE Ultragenyx Pharmaceutical Inc. | $1.5B | -3.0 | 839.4 | -67.5 | -43.0 | 17.5 | 2 | BULLISH | -51.3 |
| AGL Agilon Health, Inc. | $1.5B | -5.9 | -78.9 | -273.7 | 1.2 | 0.3 | 6 | BULLISH | 286.2 |
| TNDM Tandem Diabetes Care, Inc. | $1.2B | -20.8 | -48.0 | -8.2 | -8.3 | -7.1 | 4 | BULLISH | 31.7 |
| TDOC Teladoc Health, Inc. | $1.1B | -6.8 | -13.0 | -8.7 | -6.4 | -2.1 | 5 | BULLISH | -23.6 |
| STAA STAAR Surgical Company | $1.1B | 305.4 | 1.1 | 3.5 | 8.6 | 51.3 | 5 | BULLISH | -11.4 |
| OABIW OmniAb, Inc. | $1.1B | -14.2 | -16.9 | -16.8 | -43.7 | 66.9 | 6 | BULLISH | -14.0 |
| EDIT Editas Medicine, Inc. | $370M | -3.8 | -118.8 | 71.4 | -153.3 | 20.8 | 4 | BULLISH | -9.2 |
| VMD Viemed Healthcare, Inc. | $370M | 26.4 | 10.2 | 11.8 | 3.5 | 25.2 | 4 | BULLISH | 43.7 |
| INDP Indaptus Therapeutics, Inc. | $360M | -0.5 | -318.0 | 6437.4 | — | — | 4 | BULLISH | -6.2 |
| SSMXY Sysmex Corporation | $7.4B | 30.4 | 8.5 | 10.0 | 6.7 | 6.2 | 5 | BULLISH | 3.1 |
| ARDT Ardent Health Inc. | $1.7B | 21.6 | 6.0 | 13.5 | 1.0 | 3.3 | 5 | BULLISH | -21.1 |
| GDRX GoodRx Holdings, Inc. | $1.2B | 65.8 | 2.5 | 3.5 | 4.3 | -1.8 | 6 | BULLISH | -8.0 |
| AVHHL AVITA Medical, Inc. | $360M | -11.4 | 211.5 | -292.6 | -35.3 | 1.0 | 4 | BULLISH | 149.1 |
| GENB Generate Biomedicines, Inc. | $1.6B | -8.8 | -28.2 | -175.0 | -1065.2 | — | 1 | BULLISH | — |
| ATR AptarGroup, Inc. | $8.1B | 22.6 | 13.6 | 10.1 | 8.5 | 8.9 | 6 | BULLISH | -1.3 |
| RXRX Recursion Pharmaceuticals, Inc. | $2.0B | -4.1 | -56.6 | -99.7 | -1708.0 | -14.9 | 4 | BULLISH | -30.9 |
| XRAY DENTSPLY SIRONA Inc. | $1.9B | -3.4 | -33.0 | 9.9 | 4.1 | -0.8 | 5 | BULLISH | -26.8 |
| GRRMF Gerresheimer AG | $1.2B | -2.8 | 1.6 | 2.2 | -2.3 | 11.8 | 4 | BULLISH | -27.1 |
| TGTX TG Therapeutics, Inc. | $8.3B | 18.5 | 100.3 | 73.5 | 3.2 | 76.1 | 6 | BULLISH | 70.4 |
| GNGBY Getinge AB (publ) | $7.3B | 26.2 | 9.1 | 8.1 | 8.5 | -3.9 | 7 | BULLISH | 15.7 |
| LGND Ligand Pharmaceuticals Incorporated | $6.0B | 31.6 | 22.0 | 11.3 | 76.2 | 54.9 | 5 | BULLISH | 67.8 |
| ORKA Oruka Therapeutics, Inc. | $5.3B | -38.3 | -18.2 | -50.3 | — | — | 4 | BULLISH | 246.5 |
| IRTC iRhythm Technologies, Inc. | $4.0B | -288.0 | -9.6 | -3.4 | -0.2 | 25.6 | 6 | BULLISH | -32.1 |
| RLAY Relay Therapeutics, Inc. | $4.0B | -12.4 | -36.8 | -2519.7 | -23916.3 | 23.9 | 4 | BULLISH | 166.8 |
| VCYT Veracyte, Inc. | $3.9B | 34.8 | 8.8 | 10.7 | 17.0 | 17.3 | 8 | BULLISH | 39.9 |
| AVAH Aveanna Healthcare Holdings Inc. | $2.9B | 9.8 | 199.1 | 30.4 | 6.0 | 20.3 | 6 | BULLISH | 35.6 |
| AXGN AxoGen, Inc. | $2.2B | -75.5 | -10.3 | -6.5 | 3.1 | 24.3 | 4 | BULLISH | 177.2 |
| BHVN Biohaven Ltd. | $2.1B | -3.3 | -799.5 | -1083.0 | — | — | 3 | BULLISH | -10.9 |
| ZYME Zymeworks Inc. | $2.0B | -14.4 | -72.3 | -156.9 | -980.8 | -69.8 | 2 | BULLISH | 56.5 |
| SAEYY Redcare Pharmacy N.V. | $1.7B | -37.9 | -8.7 | -1.2 | 0.6 | 20.5 | 2 | BULLISH | -5.2 |
| TGLVY Top Glove Corporation Bhd. | $1.7B | 25.3 | 6.3 | 8.5 | 12.6 | 21.4 | 8 | BULLISH | 56.4 |
| KMTS Kestra Medical Technologies, Ltd. | $1.7B | -11.3 | -73.7 | -113.5 | -142.3 | 191.6 | 3 | BULLISH | 10.3 |
| ABSI Absci Corporation | $1.6B | -14.4 | -57.7 | -213.1 | -10443.4 | -62.3 | 5 | BULLISH | 164.0 |
| NTLA Intellia Therapeutics, Inc. | $1.6B | -3.8 | -55.4 | -92.1 | -1392.3 | 12.6 | 5 | BULLISH | -10.0 |
| TRAX First Tracks Biotherapeutics Inc | $1.6B | — | — | — | — | — | — | BULLISH | — |
| NWKHY Netcare Limited | $1.4B | 12.3 | 16.9 | 8.1 | 6.7 | 5.0 | 7 | BULLISH | 59.5 |
| LBRX LB Pharmaceuticals Inc Common Stock | $1.2B | -13.3 | -25.8 | -768.9 | — | — | 2 | BULLISH | 138.5 |
| PRCT PROCEPT BioRobotics Corporation | $1.1B | -10.4 | -30.2 | -47.6 | -28.4 | 22.7 | 2 | BULLISH | -44.4 |
| LMRI Lumexa Imaging Holdings, Inc. Common Stock | $1.1B | -30.8 | -3.9 | 0.1 | 1.0 | — | 3 | BULLISH | — |
| CSTL Castle Biosciences, Inc. | $1.0B | -55.7 | -4.2 | -10.6 | -2.0 | 3.2 | 4 | BULLISH | 53.1 |
| ARRJF Arjo AB (publ) | $920M | 25.4 | 4.6 | 4.4 | 2.0 | -2.0 | 6 | BULLISH | 3.1 |
| ENTX Entera Bio Ltd. | $510M | -9.0 | -138.9 | 314.4 | — | -100.0 | 1 | BULLISH | 33.0 |
| PRGO Perrigo Company plc | $2.2B | -1.3 | -49.6 | 3.1 | 7.3 | -4.2 | 4 | BULLISH | -25.8 |
| HSTM HealthStream, Inc. | $1.1B | 47.2 | 6.0 | 6.5 | 8.0 | 8.8 | 8 | BULLISH | 30.0 |
| ELVN Enliven Therapeutics, Inc. | $3.0B | -27.0 | -15.3 | -6535.0 | — | — | 3 | BULLISH | 109.2 |
| NAUT Nautilus Biotechnolgy, Inc. | $410M | -6.8 | -41.0 | -89.2 | -6682.1 | — | 2 | BULLISH | 137.8 |
| BRKR Bruker Corporation | $8.8B | -88.4 | -3.4 | 3.0 | -6.2 | 1.6 | 6 | BULLISH | 60.6 |
| COGT Cogent Biosciences, Inc. | $5.4B | -13.9 | -109.7 | 1964.0 | — | — | 3 | BULLISH | 99.0 |
| ADPT Adaptive Biotechnologies Corporation | $4.1B | -69.4 | -39.6 | -14.1 | -55.6 | 50.1 | 5 | BULLISH | 65.7 |
| PRTA Prothena Corporation plc | $420M | -10.9 | -14.4 | -871.5 | -1839.9 | 427.3 | 5 | BULLISH | -12.2 |
| OPHLY Ono Pharmaceutical Co., Ltd. | $7.4B | 15.2 | 9.5 | 11.3 | 20.8 | 3.3 | 9 | BULLISH | 29.2 |
| CHE Chemed Corporation | $6.7B | 25.9 | 29.1 | 22.7 | 10.4 | 5.2 | 6 | BULLISH | 22.3 |
| CNVVY ConvaTec Group Plc | $6.3B | 51.3 | 7.6 | 10.2 | 4.4 | 5.5 | 5 | BULLISH | 1.2 |
| KOD Kodiak Sciences Inc. | $5.5B | -23.0 | -368.4 | -630.1 | — | — | 1 | BULLISH | 415.4 |
| DSRLF DiaSorin S.p.A. | $4.4B | 25.5 | 14.2 | 8.9 | 14.0 | 46.3 | 5 | BULLISH | -2.4 |
| ICUI ICU Medical, Inc. | $4.2B | 137.3 | 1.4 | 2.7 | 3.5 | -9.0 | 6 | BULLISH | 35.4 |
| CDNA CareDx, Inc | $3.6B | 33.7 | 29.5 | -2.5 | 83.8 | 34.4 | 8 | BULLISH | 397.1 |
| CZMWY Carl Zeiss Meditec AG | $3.5B | 20.8 | 5.6 | 4.8 | 9.8 | 22.1 | 7 | BULLISH | -26.6 |
| SZUKF Suzuken Co., Ltd. | $2.4B | 10.6 | 9.3 | 8.6 | 0.5 | 5.0 | 4 | BULLISH | 18.9 |
| DRWKF Drägerwerk AG & Co. KGaA | $2.3B | 11.4 | 11.0 | 9.8 | 3.5 | 6.5 | 9 | BULLISH | 36.8 |
| ADUS Addus HomeCare Corporation | $2.3B | 21.5 | 9.7 | 9.6 | 7.3 | 15.9 | 6 | BULLISH | 0.6 |
| XNCR Xencor, Inc. | $1.9B | -13.6 | -29.1 | -152.4 | -42.4 | -36.1 | 2 | BULLISH | 110.2 |
| SRPT Sarepta Therapeutics, Inc. | $1.9B | -13.2 | -9.5 | -6.3 | -1.2 | -20.4 | 4 | BULLISH | -17.8 |
| XERS Xeris Biopharma Holdings, Inc. | $1.9B | -109.5 | 118.2 | 18.3 | -33.8 | 36.3 | 6 | BULLISH | 14.3 |
| PNTG The Pennant Group, Inc. | $1.5B | 45.0 | 9.6 | 5.5 | 3.0 | 37.9 | 6 | BULLISH | 71.5 |
| SPTX Seaport Therapeutics, Inc. Common Stock | $1.1B | — | — | — | — | — | — | BULLISH | — |
| AMPH Amphastar Pharmaceuticals, Inc. | $1.1B | 15.0 | 10.3 | 7.5 | 16.5 | 1.4 | 6 | BULLISH | 9.5 |
| SLN Silence Therapeutics plc | $930M | -5.2 | -90.4 | 157.8 | — | -97.6 | 1 | BULLISH | 176.1 |
| HAE Haemonetics Corporation | $5.4B | 57.6 | 11.2 | 10.1 | 9.7 | 0.4 | 8 | BULLISH | 131.1 |
| VCEL Vericel Corporation | $2.2B | 86.1 | 7.2 | 5.9 | 2.8 | 23.0 | 7 | BULLISH | 12.7 |
| IDGXF Integrated Diagnostics Holdings plc | $340M | 9.9 | 41.4 | 38.4 | 13.8 | 46.8 | 8 | BULLISH | 10.8 |
| OPCH Option Care Health, Inc. | $4.7B | 23.5 | 16.0 | 10.6 | 3.7 | 5.9 | 5 | BULLISH | 12.4 |
| ESTA Establishment Labs Holdings Inc. | $1.9B | -53.2 | -175.3 | -6.9 | -17.4 | 38.6 | 5 | BULLISH | 35.7 |
| NBTX Nanobiotix S.A. | $1.5B | -27.6 | 104.2 | 62.0 | -626.0 | 49.1 | 4 | BULLISH | 125.3 |
| CMOPF Cosmo N.V. | $1.1B | -158.1 | -1.2 | -2.9 | -9.5 | -43.8 | 1 | BULLISH | -16.0 |
| MLTX MoonLake Immunotherapeutics | $1.0B | -3.2 | -67.4 | 2902.7 | — | — | 1 | BULLISH | 22.2 |
| LQDA Liquidia Corporation | $3.8B | 29.3 | 131.8 | 391.9 | 43.5 | 2233.6 | 6 | BULLISH | 100.9 |
| STOK Stoke Therapeutics, Inc. | $1.6B | -7.8 | -61.1 | -318.5 | -660.8 | -86.2 | 2 | BULLISH | -20.0 |
| PHAR Pharming Group N.V. | $710M | 82.6 | 3.6 | 3.2 | 1.8 | 7.8 | 7 | BULLISH | -8.0 |
| TCMD Tactile Systems Technology, Inc. | $540M | 21.9 | 11.9 | 13.8 | 9.1 | 17.2 | 8 | BULLISH | 59.4 |
| SGHT Sight Sciences, Inc. | $500M | -16.4 | -48.4 | -145.7 | -19.0 | 9.3 | 4 | BULLISH | 78.7 |
| CARL Carlsmed, Inc. | $400M | -11.2 | -43.8 | -122.7 | -55.5 | — | 2 | BULLISH | 13.1 |
| CCCC C4 Therapeutics, Inc. | $380M | -3.4 | -48.1 | -175.0 | -355.9 | 2.3 | 4 | BULLISH | 28.3 |
| NGNE Neurogene Inc. | $370M | -5.5 | -45.3 | -111469.0 | — | — | 2 | BULLISH | -5.1 |
| FENC Fennec Pharmaceuticals Inc. | $350M | -82.6 | -18.6 | -76.2 | 11.0 | 77.8 | 6 | BULLISH | 23.2 |
| HLUBF H. Lundbeck A/S | $7.3B | 13.5 | 15.2 | 12.6 | 17.6 | 10.1 | 7 | BULLISH | 22.5 |
| HKMPY Hikma Pharmaceuticals PLC | $4.6B | 12.8 | 15.3 | 12.1 | 12.9 | 6.1 | 7 | BULLISH | -6.3 |
| PGNY Progyny, Inc. | $2.2B | 28.7 | 16.2 | 30.2 | 8.0 | 5.5 | 7 | BULLISH | 42.7 |
| KHTRF Knight Therapeutics Inc. | $810M | 76.7 | 1.9 | 2.6 | -2.3 | 42.4 | 8 | BULLISH | 97.6 |
| STLN Starling Oncology, Inc. | $670M | — | — | — | — | — | — | BULLISH | — |
| PBYI Puma Biotechnology, Inc. | $570M | 19.9 | 22.0 | 52.8 | 14.5 | -2.9 | 6 | BULLISH | 101.5 |
| ESAIY Eisai Co., Ltd. | $9.2B | 33.8 | 3.8 | 3.3 | 7.8 | 248.0 | 6 | BULLISH | 5.1 |
| AKBLF ALK-Abelló A/S | $7.4B | 39.9 | 21.2 | 23.9 | 18.9 | 16.4 | 8 | BULLISH | 12.8 |
| LVZPF Livzon Pharmaceutical Group Inc. | $6.1B | 15.9 | 11.5 | 16.4 | 15.3 | -14.4 | 4 | BULLISH | 0.0 |
| AMBBY Ambu A/S | $3.2B | 41.9 | 8.5 | 9.0 | 9.5 | -411.9 | 6 | BULLISH | -28.5 |
| PRVA Privia Health Group, Inc. | $2.9B | 96.6 | 0.0 | 0.0 | 1.4 | 24.1 | 1 | BULLISH | -15.1 |
| EKTAY Elekta AB (publ) | $2.2B | -63.0 | -4.4 | -49.1 | 7.5 | -7.8 | 4 | BULLISH | 12.1 |
| VTRLY Vitrolife AB (publ) | $1.4B | -3.1 | -46.2 | -41.3 | 14.3 | -2.0 | 5 | BULLISH | -34.0 |
| OPK OPKO Health, Inc. | $1.2B | -17.0 | -5.9 | -3.0 | -5.1 | -11.5 | 2 | BULLISH | 11.7 |
| ERAS Erasca, Inc. | $5.0B | -15.6 | -78.2 | -87.5 | — | — | 2 | BULLISH | 532.6 |
| NVST Envista Holdings Corp | $3.8B | 40.1 | 3.1 | 3.2 | 7.4 | 11.9 | 7 | BULLISH | 17.6 |
| EOLS Evolus, Inc. | $460M | -14.6 | 138.6 | -20.7 | -9.6 | 13.9 | 5 | BULLISH | 5.8 |
| KMDA Kamada Ltd. | $450M | 20.8 | 8.4 | 11.0 | 16.9 | 13.2 | 7 | BULLISH | 13.8 |
| LIVN LivaNova PLC | $4.4B | 23.3 | 15.4 | 30.2 | 27.8 | 12.4 | 8 | BULLISH | 48.6 |
| IMCR Immunocore Holdings plc | $1.6B | -179.1 | -2.3 | -472.0 | -0.7 | 13.4 | 4 | BULLISH | -2.5 |
| CRON Cronos Group Inc. | $1.2B | 17.8 | 6.5 | 5.4 | 60.5 | 72.9 | 7 | BULLISH | 35.6 |
| JANX Janux Therapeutics, Inc. | $1.0B | -10.8 | -10.7 | 516.9 | -214.0 | 7162.0 | 4 | BULLISH | -34.0 |
| MLAB Mesa Laboratories, Inc. | $720M | 152.4 | 2.7 | 4.4 | 4.7 | 3.0 | 8 | BULLISH | 71.1 |
| IOBCF Ion Beam Applications S.A. | $550M | 19.7 | 20.6 | 14.0 | 2.9 | 7.0 | 5 | BULLISH | 39.5 |
| PCRX Pacira BioSciences, Inc. | $1.4B | 103.4 | 2.0 | 1.8 | 2.4 | 5.7 | 8 | BULLISH | 70.6 |
| AHG Akso Health Group | $1.1B | -20.7 | -50.1 | -44.9 | -546.5 | 22.7 | 4 | BULLISH | -15.8 |
| SKHHY Sonic Healthcare Limited | $6.5B | 15.3 | 7.3 | 6.2 | 6.2 | 52.7 | 5 | BULLISH | -7.1 |
| PHVS Pharvaris N.V. | $2.2B | -10.8 | -70.7 | 860.9 | — | — | 4 | BULLISH | 43.8 |
| ZBIO Zenas BioPharma, Inc. | $1.8B | -3.0 | -199.0 | 5842.1 | -11145.6 | -93.3 | 2 | BULLISH | -9.5 |
| VOR Vor Biopharma Inc. | $990M | 0.1 | -73.6 | 22.2 | — | — | 3 | BULLISH | -26.6 |
| FLGT Fulgent Genetics, Inc. | $550M | -7.5 | -8.0 | -12.6 | -34.6 | 6.8 | 4 | BULLISH | -7.7 |
| DRUG Bright Minds Biosciences Inc. | $520M | -26.7 | -13.7 | -105758.3 | — | — | 3 | BULLISH | -5.9 |
| CHEOY Cochlear Limited | $6.7B | 62.2 | 7.8 | 11.6 | -1.2 | -1.2 | 6 | BULLISH | -47.7 |
| CLOV Clover Health Investments, Corp. | $2.4B | -117.3 | -5.1 | -8.3 | 3.8 | 54.0 | 4 | BULLISH | 25.7 |
| OMCL Omnicell, Inc. | $1.7B | 42.3 | 3.1 | 3.2 | 7.8 | 8.5 | 9 | BULLISH | 17.7 |
| MTHRY M3, Inc. | $8.2B | 27.1 | 12.1 | 16.9 | 10.1 | 17.7 | 7 | BULLISH | -18.0 |
| BRVE Braveheart Bio, Inc. | $1.5B | — | — | — | — | — | — | BULLISH | — |
| DMRA Damora Therapeutics, Inc. | $1.3B | — | — | — | — | — | — | BULLISH | — |
| PTCHF PureTech Health plc | $390M | 156.7 | 0.2 | 50.8 | 1890.6 | 7.7 | 4 | BULLISH | -5.4 |
| TYRA Tyra Biosciences, Inc. | $1.2B | -8.9 | -45.3 | -2390.9 | — | — | 2 | BULLISH | 46.6 |
| ARVN Arvinas, Inc. | $470M | 39.5 | 1.6 | -519.3 | 67.8 | -15.0 | 4 | BULLISH | -21.2 |
| SHWGF Shandong Weigao Group Medical Polymer Company Limited | $1.9B | 9.4 | 5.6 | 7.4 | 11.3 | 2.2 | 6 | BULLISH | -39.1 |
| EBOSY EBOS Group Limited | $1.0B | 15.1 | 5.0 | 4.4 | 1.7 | -8.1 | 6 | BULLISH | -39.5 |
| JCRRF JCR Pharmaceuticals Co., Ltd. | $460M | 76.2 | 1.9 | -0.5 | -19.7 | 66.6 | 4 | BULLISH | -17.1 |
| SHTDF Sinopharm Group Co. Ltd. | $6.3B | 6.0 | 8.4 | 10.2 | 1.2 | -2.2 | 6 | BULLISH | -17.8 |
| HIMS Hims & Hers Health, Inc. | $6.2B | -47.9 | -32.0 | -7.1 | -11.5 | 28.0 | 4 | BULLISH | -39.2 |
| SHPMY Shanghai Pharmaceuticals Holding Co., Ltd | $5.1B | 12.8 | 6.2 | 6.5 | 2.9 | 4.1 | 5 | BULLISH | -13.8 |
| SNPHY Santen Pharmaceutical Co., Ltd. | $3.6B | 14.7 | 13.6 | 14.9 | 10.4 | 0.9 | 8 | BULLISH | 7.8 |
| NUTX Nutex Health, Inc. | $1.4B | 8.0 | 49.2 | 53.9 | 31.2 | 6.9 | 7 | BULLISH | 64.2 |
| KURA Kura Oncology, Inc. | $850M | -3.1 | -167.7 | 56.3 | -327.3 | -7.3 | 1 | BULLISH | -2.9 |
| RZLT Rezolute, Inc. | $370M | -5.5 | -59.0 | 1060.6 | — | — | 2 | BULLISH | -55.2 |
| OBIO Orchestra BioMed Holdings, Inc. | $340M | -6.0 | -397.3 | 468.3 | -26994.3 | 986.1 | 4 | BULLISH | 51.6 |
| EBS Emergent BioSolutions Inc. | $320M | -2.0 | -40.3 | -5.5 | -76.9 | -9.6 | 5 | BULLISH | -26.8 |
| APNHY Aspen Pharmacare Holdings Limited | $4.2B | 26.7 | 3.2 | 5.3 | 6.6 | -20.1 | 7 | BULLISH | 69.4 |
| DYN Dyne Therapeutics, Inc. | $2.9B | -5.0 | -81.6 | 240.4 | — | — | 2 | BULLISH | -29.8 |
| CSWYF China Shineway Pharmaceutical Group Limited | $760M | 5.9 | 19.9 | 46.7 | 21.6 | 1081.8 | 8 | BULLISH | 0.0 |
| MAHLY MediPal Holdings Corporation | $4.1B | 14.8 | 7.5 | 8.7 | 1.4 | 5.9 | 7 | BULLISH | 23.9 |
| INSP Inspire Medical Systems, Inc. | $2.1B | 15.3 | 18.0 | 19.7 | 0.2 | 4.3 | 8 | BULLISH | -9.2 |
| DNA Ginkgo Bioworks Holdings, Inc. | $670M | -2.7 | -56.3 | -44.0 | -231.7 | -51.5 | 2 | BULLISH | -0.4 |
| GMRS GMR Solutions Inc. | $580M | — | — | — | — | — | — | BULLISH | — |
| EVH Evolent Health, Inc. | $540M | -1.0 | -79.0 | -1.8 | -4.3 | -4.5 | 5 | BULLISH | -43.3 |
| ACAD Acadia Pharmaceuticals Inc. | $3.4B | 9.0 | 35.7 | 63.9 | 10.2 | 11.8 | 5 | LEAN BULL | -11.6 |
| QURE uniQure N.V. | $1.6B | -6.1 | -157.6 | 37.9 | -1387.8 | 30.2 | 4 | LEAN BULL | -63.2 |
| IOVA Iovance Biotherapeutics, Inc. | $6.4B | -20.1 | -40.4 | -49.1 | -47.6 | 34.5 | 6 | LEAN BULL | 541.1 |
| ATEC Alphatec Holdings, Inc. | $1.7B | -15.8 | -623.1 | -7.6 | -12.1 | 19.5 | 5 | LEAN BULL | -30.9 |
| VREX Varex Imaging Corporation | $780M | 35.2 | 4.6 | 7.6 | 7.5 | 5.3 | 6 | LEAN BULL | 54.8 |
| EMBC Embecta Corp. | $380M | 4.3 | -13.6 | 26.3 | 7.8 | -7.6 | 5 | LEAN BULL | -53.5 |
| PTGX Protagonist Therapeutics, Inc. | $9.0B | 115.9 | 11.0 | 84.1 | 76.3 | 34.8 | 7 | LEAN BULL | 88.9 |
| MIRM Mirum Pharmaceuticals, Inc. | $5.2B | -5.9 | -703.0 | -27.3 | -38.1 | 44.0 | 3 | LEAN BULL | 19.9 |
| DFTX Definium Therapeutics, Inc. | $4.8B | -11.0 | -25.7 | 82.4 | — | — | 2 | LEAN BULL | — |
| NEO NeoGenomics, Inc. | $2.2B | -44.4 | -6.3 | -4.8 | 1.1 | 11.2 | 5 | LEAN BULL | 77.1 |
| VERA Vera Therapeutics, Inc. | $2.0B | -5.2 | -91.8 | 2030.6 | — | — | 1 | LEAN BULL | 1.7 |
| BCRX BioCryst Pharmaceuticals, Inc. | $1.9B | -5.7 | 87.8 | 62.3 | 35.9 | 68.7 | 5 | LEAN BULL | 14.5 |
| CMPS COMPASS Pathways plc | $1.6B | -2.2 | -319.1 | 48.8 | — | — | 2 | LEAN BULL | 87.8 |
| COLL Collegium Pharmaceutical, Inc. | $750M | 15.1 | 17.6 | 9.4 | -7.5 | 14.3 | 6 | LEAN BULL | -33.3 |
| SOPH SOPHiA GENETICS S.A. | $630M | -6.7 | -101.2 | -155.2 | -95.9 | 23.6 | 3 | LEAN BULL | 87.4 |
| CERS Cerus Corporation | $470M | -66.9 | -10.8 | -7.4 | -5.1 | 15.1 | 5 | LEAN BULL | 57.1 |
| OVID Ovid Therapeutics Inc. | $420M | -5.1 | -26.0 | -43.7 | -2047.6 | -76.2 | 3 | LEAN BULL | 53.1 |
| ABCL AbCellera Biologics Inc. | $3.8B | -24.7 | -17.3 | -36.2 | -1368.6 | 101.3 | 4 | LEAN BULL | 136.4 |
| SENS Senseonics Holdings, Inc. | $400M | -4.1 | -118.2 | -901.4 | -253.4 | 79.0 | 3 | LEAN BULL | 25.5 |
| LMAT LeMaitre Vascular, Inc. | $1.9B | 28.6 | 16.8 | 25.6 | 24.2 | 11.8 | 8 | LEAN BULL | -7.8 |
| SI Shoulder Innovations, Inc. | $410M | -11.3 | -28.2 | -69.1 | -59.1 | — | 1 | LEAN BULL | 58.1 |
| OFIX Orthofix Medical Inc. | $400M | -6.5 | -13.9 | -3.6 | -7.5 | 3.0 | 6 | LEAN BULL | -37.6 |
| SDGCF Sundrug Co.,Ltd. | $3.3B | 13.2 | 11.4 | 10.6 | 3.7 | 4.9 | 6 | LEAN BULL | 0.0 |
| ARHCF Alfresa Holdings Corporation | $2.5B | 11.2 | 5.7 | 7.8 | 0.2 | 3.6 | 5 | LEAN BULL | 17.9 |
| TSMRF Tsumura & Co. | $1.7B | 9.1 | 9.9 | 6.6 | 13.0 | 10.7 | 4 | LEAN BULL | 0.0 |
| SWGHF Sawai Group Holdings Co., Ltd. | $1.3B | 22.7 | 4.3 | 4.6 | 4.7 | 11.4 | 4 | LEAN BULL | 0.0 |
| TWAPF Towa Pharmaceutical Co., Ltd. | $1.3B | 20.8 | 4.7 | 3.2 | 7.7 | 7.1 | 7 | LEAN BULL | 54.4 |
| KKPCF Kaken Pharmaceutical Co., Ltd. | $980M | 13.9 | 6.9 | 7.9 | 28.0 | -6.6 | 4 | LEAN BULL | 8.3 |
| OGN Organon & Co. | $3.6B | 17.4 | 24.0 | 6.0 | 6.9 | -2.5 | 5 | LEAN BULL | 95.6 |
| ACHC Acadia Healthcare Company, Inc. | $2.9B | -2.4 | -44.5 | 6.1 | 1.3 | 4.3 | 4 | LEAN BULL | 28.6 |
| ANAB AnaptysBio, Inc. | $1.5B | 7.4 | -1146.3 | 466.0 | 668.9 | 92.9 | 5 | LEAN BULL | 109.4 |
| TKNO Alpha Teknova, Inc. | $340M | -24.9 | -24.2 | -17.2 | -26.0 | 12.3 | 4 | LEAN BULL | 44.2 |
| TWST Twist Bioscience Corporation | $9.2B | -77.7 | -29.6 | -29.2 | -29.6 | 19.2 | 2 | LEAN BULL | 407.5 |
| PRAX Praxis Precision Medicines, Inc. | $7.1B | -21.7 | -38.9 | -51.2 | — | -100.0 | 4 | LEAN BULL | 53.5 |
| INVA Innoviva, Inc. | $1.5B | 4.3 | 36.7 | 15.0 | -69.8 | 19.8 | 7 | LEAN BULL | 19.2 |
| YDES YD Bio Limited Ordinary Shares | $350M | — | — | — | — | — | — | LEAN BULL | -62.1 |
| ZURA Zura Bio Limited | $320M | -3.8 | -65.4 | 806.5 | — | — | 2 | LEAN BULL | 10.7 |
| INNV Innovage Holding Corp. | $1.3B | -441.4 | -1.1 | -89.6 | 3.2 | 16.4 | 6 | LEAN BULL | 81.3 |
| PBH Prestige Consumer Healthcare Inc. | $2.3B | 13.3 | 9.1 | 5.5 | 11.0 | -1.4 | 4 | LEAN BULL | -23.4 |
| ACRS Aclaris Therapeutics, Inc. | $550M | -6.6 | -59.1 | -206.5 | -1320.1 | -51.0 | 3 | LEAN BULL | 69.2 |
| ITGR Integer Holdings Corporation | $4.3B | 34.3 | 7.5 | 5.4 | 5.1 | 2.6 | 7 | LEAN BULL | 80.3 |
| PAHC Phibro Animal Health Corporation | $1.6B | 15.4 | 29.7 | 13.2 | 5.5 | 17.1 | 7 | LEAN BULL | -8.9 |
| WVE Wave Life Sciences Ltd. | $630M | -3.4 | -80.0 | -1243.7 | -470.5 | -35.1 | 2 | LEAN BULL | -52.2 |
| EWTX Edgewise Therapeutics, Inc. | $4.2B | -21.6 | -38.0 | 1912.5 | — | — | 1 | LEAN BULL | 152.6 |
| TXG 10x Genomics, Inc. | $9.3B | -141.7 | -9.4 | -19.8 | -11.9 | -4.3 | 5 | LEAN BULL | 515.2 |
| PSNL Personalis, Inc. | $1.7B | -14.6 | -50.3 | -149.3 | -141.7 | -13.3 | 2 | LEAN BULL | 65.3 |
| IUSDF AS ONE Corporation | $1.0B | 19.1 | 12.2 | 13.4 | 8.1 | 5.7 | 6 | LEAN BULL | -39.5 |
| MSMKF MatsukiyoCocokara & Co. | $5.8B | 17.3 | 11.1 | 12.6 | 5.1 | 5.7 | 8 | NEUTRAL | -16.3 |
| NPNKF Nippon Shinyaku Co., Ltd. | $1.6B | 7.2 | 11.6 | 12.5 | 20.6 | 12.8 | 4 | NEUTRAL | -1.1 |
| BBNX Beta Bionics, Inc. | $860M | -9.8 | -23.9 | -43.7 | -68.6 | 86.8 | 4 | NEUTRAL | -24.8 |
| AHCO AdaptHealth Corp. | $820M | -3.5 | -15.5 | -0.2 | -18.1 | 22.9 | 6 | NEUTRAL | -35.9 |
| LWSCF Sienna Senior Living Inc. | $1.6B | 38.2 | 6.7 | 3.9 | 4.4 | 16.2 | 7 | NEUTRAL | 1.6 |
| KYKOF Kyowa Kirin Co., Ltd. | $8.1B | 15.4 | 9.3 | 14.2 | 12.8 | 7.4 | 7 | NEUTRAL | -9.5 |
| CYDY CytoDyn Inc. | $380M | -4.9 | 57.8 | 24.6 | — | 100.0 | 4 | NEUTRAL | -16.7 |
| CGEM Cullinan Therapeutics, Inc. | $880M | -4.5 | -50.3 | 1635.6 | — | — | 1 | NEUTRAL | 93.0 |
| PMI Picard Medical, Inc. | $730M | -0.3 | -1631.2 | -469.0 | -191.6 | — | 2 | NEUTRAL | 50.5 |
| BCHMF Bachem Holding AG | $6.8B | 42.2 | 10.6 | 8.2 | 15.4 | 4.3 | 3 | NEUTRAL | 24.7 |
| ALBHF Alibaba Health Information Technology Limited | $6.3B | 19.9 | 11.2 | 20.8 | 3.8 | -36.2 | 3 | NEUTRAL | -49.0 |
| BUHPF Bumrungrad Hospital Public Company Limited | $4.8B | 21.0 | 27.3 | 37.3 | 30.3 | 1.6 | 5 | NEUTRAL | 23.7 |
| ANSLY Ansell Limited | $4.7B | 22.3 | 10.6 | 9.5 | 10.8 | 7.1 | 8 | NEUTRAL | 43.8 |
| TCHBF Tecan Group AG | $3.5B | -26.9 | -9.7 | 2.8 | 2.9 | -4.2 | 6 | NEUTRAL | 45.2 |
| XENE Xenon Pharmaceuticals Inc. | $3.4B | -7.6 | -43.6 | -109.7 | — | -100.0 | 3 | NEUTRAL | -13.2 |
| PBLS Parabilis Medicines, Inc. | $3.0B | — | — | — | — | — | — | NEUTRAL | — |
| OSSFF Embla Medical hf. | $1.9B | 18.3 | 10.4 | 7.7 | 10.5 | 9.9 | 7 | NEUTRAL | -5.6 |
| CSSPF NIOX Group Plc | $380M | 40.7 | 10.8 | 13.0 | 24.6 | 3.5 | 7 | NEUTRAL | -2.3 |
| STTK Shattuck Labs, Inc. | $550M | -11.2 | -39.2 | -29.3 | — | -66.6 | 4 | NEUTRAL | 182.0 |
| VHIBF Vitalhub Corp. | $340M | 62.9 | 3.3 | 10.7 | 6.1 | 53.9 | 7 | NEUTRAL | -34.9 |
| HUMDF Hua Medicine (Shanghai) Ltd. | $300M | -18.4 | -10.3 | -30.2 | -8.0 | 73.9 | 3 | NEUTRAL | -26.1 |
| HSIC Henry Schein, Inc. | $9.5B | 24.5 | 12.2 | 8.7 | 2.7 | 6.5 | 7 | NEUTRAL | 33.7 |
| RGEDF Chemical Works of Gedeon Richter Plc | $7.4B | 10.4 | 16.2 | 24.3 | 15.9 | 1.8 | 5 | NEUTRAL | 20.6 |
| LYCA Lycia Therapeutics Inc. | $1.6B | — | — | — | — | — | — | N/A | — |
| CTEV Claritev Corporation | $400M | -1.3 | 169.3 | 0.9 | -23.0 | 110.3 | 4 | NEUTRAL | -67.8 |
| TSUSF Tsuruha Holdings Inc. | $4.2B | 16.8 | 6.2 | 12.0 | 2.8 | 16.1 | 5 | NEUTRAL | 0.0 |
| ODTX Odyssey Therapeutics, Inc. | $940M | — | — | — | — | — | — | NEUTRAL | — |
| JBIO Jade Biosciences, Inc. | $930M | -5.2 | -47.8 | 629.9 | — | — | 3 | NEUTRAL | 43.2 |
| DNPUF Sumitomo Pharma Co., Ltd. | $6.4B | 6.9 | 39.1 | 10.3 | 13.1 | 14.5 | 6 | NEUTRAL | 5.6 |
| SGFEF Siegfried Holding AG | $3.9B | 18.5 | 17.0 | 9.4 | 10.8 | 3.4 | 4 | NEUTRAL | -15.8 |
| RKAGY RHÃN-KLINIKUM Aktiengesellschaft | $1.1B | 22.3 | 2.8 | 3.1 | 2.1 | 2.5 | 6 | NEUTRAL | 10.7 |
| SVRA Savara Inc. | $870M | -8.6 | -105.5 | -15438.9 | — | — | 2 | NEUTRAL | 14.6 |
| MDRX Veradigm Inc. | $830M | -7.4 | 4.3 | 7.0 | 6.2 | -39.7 | 5 | NEUTRAL | 6.4 |
| INDV Indivior Pharmaceuticals Inc | $4.3B | 12.1 | -152.4 | 528.3 | 35.6 | 13.5 | 4 | NEUTRAL | 40.3 |
| ALMS Alumis Inc. | $880M | -1.9 | -93.6 | 2645.2 | -8557.2 | -63.1 | 2 | NEUTRAL | 48.2 |
| CRSP CRISPR Therapeutics AG | $4.8B | -11.1 | -26.1 | -253.2 | -895.3 | -62.7 | 3 | NEUTRAL | -17.7 |
| ZLAB Zai Lab Limited | $2.7B | -13.3 | -26.9 | -85.4 | -47.8 | 5.1 | 3 | NEUTRAL | -12.5 |
| USPH U.S. Physical Therapy, Inc. | $1.3B | 501.4 | -1.3 | 7.7 | 0.7 | 17.1 | 5 | NEUTRAL | -4.0 |
| AORT Artivion, Inc. | $1.1B | -382.9 | -0.7 | -3.4 | -10.7 | 16.4 | 4 | NEUTRAL | -48.8 |
| IONS Ionis Pharmaceuticals, Inc. | $7.1B | -12.7 | -105.4 | -58.5 | -42.8 | -7.4 | 3 | NEUTRAL | -38.5 |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.2B | -29.6 | -200.0 | 144.2 | -69.2 | 53.5 | 4 | NEUTRAL | -17.6 |
| SRRK Scholar Rock Holding Corporation | $5.0B | -13.0 | -167.8 | 931.3 | — | — | 2 | NEUTRAL | 41.8 |
| MCTA Charming Medical Limited Class A Ordinary Shares | $450M | — | — | — | — | — | — | LEAN BEAR | — |
| AHICF Asahi Intecc Co., Ltd. | $5.7B | 29.6 | 20.0 | 27.8 | 14.6 | 21.6 | 9 | LEAN BEAR | 32.6 |
| GEDSF Gedeon Richter PLC | $4.5B | 10.4 | 16.4 | 22.0 | 29.6 | 4.8 | 7 | LEAN BEAR | 0.0 |
| GLPGF Lakefront Biotherapeutics | $2.1B | 3.9 | 20.2 | 39.4 | 17.4 | 259.3 | 5 | LEAN BEAR | -4.5 |
| STSEY Stratec SE | $1.7B | -572.5 | -0.2 | -0.2 | 7.0 | -4.8 | 4 | LEAN BEAR | -17.8 |
| SAFLY Safilo Group S.p.A. | $1.4B | 15.2 | 12.0 | 10.0 | 8.7 | -3.4 | 7 | LEAN BEAR | 40.1 |
| AGYTF Allergy Therapeutics plc | $760M | -4.0 | 3372.3 | -97.9 | -54.9 | 19.9 | 3 | LEAN BEAR | 36.4 |
| RGC Regencell Bioscience Holdings Limited | $3.8B | -307.6 | -128.5 | 1692.4 | — | — | 3 | LEAN BEAR | -56.0 |
| CGON CG Oncology Inc. | $5.5B | -23.7 | -26.4 | -2066.1 | -6832.8 | 1030.3 | 3 | LEAN BEAR | 44.4 |
| ENTA Enanta Pharmaceuticals, Inc. | $340M | -4.8 | -70.1 | 141.5 | -135.8 | 0.7 | 4 | LEAN BEAR | 10.0 |
| LNTH Lantheus Holdings, Inc. | $6.5B | 23.8 | 22.2 | 17.1 | 19.3 | 2.3 | 5 | LEAN BEAR | 72.2 |
| ALVOW Alvotech | $3.9B | -8.4 | 98.5 | 3.3 | -63.2 | -12.2 | 0 | LEAN BEAR | -86.3 |
| GYRE Gyre Therapeutics, Inc. | $620M | -34.7 | -15.6 | -22.3 | -36.4 | 16.8 | 3 | LEAN BEAR | -11.6 |
| NEOG Neogen Corporation | $2.7B | -48.0 | -2.7 | -0.2 | -5.3 | -0.3 | 7 | LEAN BEAR | 95.2 |
| TRVI Trevi Therapeutics, Inc. | $1.8B | -39.8 | -19.7 | -1451.7 | — | — | 3 | LEAN BEAR | 28.8 |
| AURA Aura Biosciences, Inc. | $650M | -3.6 | -53.5 | -1360.0 | — | — | 4 | LEAN BEAR | 4.9 |
| RSLBF RaySearch Laboratories AB (publ) | $510M | 31.9 | 26.1 | 21.8 | 7.2 | 1.2 | 6 | LEAN BEAR | -35.8 |
| TTRX Turn Therapeutics Inc. | $310M | -37.9 | -952.4 | 115.0 | — | — | 2 | LEAN BEAR | 123.7 |
| DNTH Dianthus Therapeutics, Inc. | $4.3B | -621.3 | -4.1 | -60.1 | -6598.6 | -60.8 | 3 | LEAN BEAR | 145.6 |
| SLDB Solid Biosciences Inc. | $630M | -3.4 | -65.5 | -1012.6 | — | — | 3 | LEAN BEAR | 9.8 |
| ANGO AngioDynamics, Inc. | $520M | -15.3 | -19.2 | -20.5 | -8.8 | 8.2 | 5 | LEAN BEAR | -1.3 |
| SRTA Strata Critical Medical, Inc. | $410M | 9.5 | 16.0 | -6.2 | -14.5 | 0.6 | 3 | LEAN BEAR | -5.0 |
| JNDOF JINS HOLDINGS Inc. | $810M | 17.8 | 22.7 | 27.1 | 5.1 | 15.0 | 6 | LEAN BEAR | 51.6 |
| HNGZY Hangzhou Tigermed Consulting Co., Ltd | $6.9B | 603.3 | 0.5 | 1.6 | -24.2 | 12.0 | 6 | LEAN BEAR | 11.2 |
| SHJBF Shanghai Junshi Biosciences Co., Ltd. | $4.8B | -70.9 | -7.1 | -6.3 | 4.4 | 29.7 | 5 | LEAN BEAR | -20.8 |
| MCVEF Medicover AB (publ) | $4.1B | 44.8 | 16.9 | 6.8 | 3.8 | 9.4 | 7 | LEAN BEAR | 0.0 |
| MDRSF Medartis Holding AG | $1.4B | 79.4 | 5.5 | 0.7 | 3.2 | 29.6 | 6 | LEAN BEAR | 72.5 |
| PTCT PTC Therapeutics, Inc. | $5.1B | -127.6 | 20.6 | -5.4 | 23.2 | -42.8 | 2 | LEAN BEAR | -6.0 |
| CELC Celcuity Inc. | $3.2B | -16.1 | -1433.7 | 1325.2 | — | — | 3 | LEAN BEAR | -10.4 |
| TSHA Taysha Gene Therapies, Inc. | $1.3B | -10.0 | -47.1 | 961.0 | — | -32.3 | 3 | LEAN BEAR | -13.1 |
| MNKD MannKind Corporation | $1.0B | -24.2 | 71.4 | 4.0 | -17.4 | 30.5 | 2 | LEAN BEAR | -36.7 |
| SUPN Supernus Pharmaceuticals, Inc. | $2.4B | -21.0 | -10.5 | -12.6 | -26.6 | 24.9 | 3 | LEAN BEAR | -22.1 |
| BFLY Butterfly Network, Inc. | $1.8B | -26.9 | -35.5 | -74.8 | -39.6 | 28.1 | 4 | LEAN BEAR | 255.9 |
| LJUIF SSY Group Limited | $1.2B | 15.0 | 6.7 | 4.6 | 13.6 | -4.4 | 5 | LEAN BEAR | 0.0 |
| KARD Kardigan, Inc. | $1.1B | — | — | — | — | — | — | LEAN BEAR | — |
| SHEZF Shenzhen Hepalink Pharmaceutical Group Co., Ltd. | $690M | 66.0 | 2.8 | 2.7 | 7.0 | -0.3 | 6 | LEAN BEAR | 0.0 |
| FDMT 4D Molecular Therapeutics, Inc. | $600M | -4.6 | -43.3 | -182.0 | -1929.0 | 278712.1 | 4 | LEAN BEAR | 5.4 |
| CLCGY Clicks Group Limited | $3.1B | 15.1 | 47.7 | 39.1 | 6.5 | 6.3 | 6 | LEAN BEAR | -39.9 |
| PTKFF PT Kalbe Farma Tbk. | $2.0B | 9.2 | 15.4 | 17.6 | 9.1 | 13.2 | 5 | LEAN BEAR | -18.5 |
| JXFGF Jinxin Fertility Group Limited | $730M | 26.6 | 1.9 | 1.8 | 7.8 | 1.4 | 7 | LEAN BEAR | 3.6 |
| FGHQF Frontage Holdings Corporation | $360M | 36.5 | 3.1 | 3.0 | 4.6 | 9.8 | 7 | LEAN BEAR | 16.8 |
| GWIN Glorywin Entertainment Group, Inc. | $360M | -26081.4 | 11.7 | 5.1 | — | — | 1 | LEAN BEAR | 229.5 |
| CLVSF CellaVision AB (publ) | $330M | 32.3 | 15.1 | 17.1 | 16.3 | -1.9 | 6 | LEAN BEAR | -27.4 |
| NURPF Neuren Pharmaceuticals Limited | $1.8B | 119.7 | 6.2 | 22.4 | 14.6 | -68.5 | 5 | LEAN BEAR | 20.8 |
| CNMD CONMED Corporation | $1.5B | 24.7 | 5.5 | 5.2 | 6.7 | 3.4 | 7 | LEAN BEAR | -3.5 |
| BJTRF Beijing Tong Ren Tang Chinese Medicine Company Limited | $540M | 10.1 | 20.8 | 23.4 | 32.9 | 697.9 | 9 | LEAN BEAR | 0.0 |
| COGZF Cogstate Limited | $410M | 35.0 | 22.4 | 37.3 | 22.4 | -14.8 | 3 | LEAN BEAR | 44.2 |
| IMNM Immunome, Inc. | $2.1B | -7.3 | -64.0 | -2208.4 | — | -100.0 | 4 | LEAN BEAR | 13.0 |
| ASTH Astrana Health, Inc. | $1.9B | 44.2 | 5.1 | 4.7 | 2.0 | 58.9 | 5 | LEAN BEAR | 10.9 |
| CLHLF COLTENE Holding AG | $330M | 19.5 | 16.1 | 12.5 | 3.6 | -2.5 | 5 | LEAN BEAR | -8.4 |
| ADRX ADARx Pharmaceuticals, Inc. | $1.9B | — | — | — | — | — | — | LEAN BEAR | — |
| ANNX Annexon, Inc. | $610M | -3.4 | -105.3 | -11323.3 | — | — | 2 | BEARISH | 14.1 |
| ETON Eton Pharmaceuticals, Inc. | $1.4B | 110.7 | 36.0 | 33.3 | 30.8 | 81.5 | 7 | BEARISH | 180.3 |
| HROW Harrow Health, Inc. | $1.1B | -29.5 | -114.8 | 1.9 | -24.4 | 21.1 | 5 | BEARISH | -23.1 |
| GLUE Monte Rosa Therapeutics, Inc. | $920M | -4.9 | -42.7 | 149.9 | -483.9 | -83.9 | 3 | BEARISH | -11.9 |
| LTGO Latigo Biotherapeutics Inc. | $900M | — | — | — | — | — | — | BEARISH | — |
| SANA Sana Biotechnology, Inc. | $700M | -3.4 | -152.9 | -242.3 | — | — | 3 | BEARISH | -49.9 |
| OCS Oculis Holding AG | $490M | -4.7 | -44.0 | -31.0 | — | -6.9 | 3 | BEARISH | -63.0 |
| RLMD Relmada Therapeutics, Inc. | $350M | -3.6 | -55.7 | 460.5 | — | — | 3 | BEARISH | 43.8 |
| STVN Stevanato Group S.p.A. | $5.3B | 36.1 | 9.1 | 7.2 | 7.6 | 6.7 | 6 | BEARISH | -25.1 |
| ALLO Allogene Therapeutics, Inc. | $430M | -1.9 | -42.4 | -81.9 | -919.8 | — | 5 | BEARISH | 5.7 |
| WGS GeneDx Holdings Corp. | $1.7B | -17.8 | -40.8 | -17.2 | -15.5 | 25.4 | 4 | BEARISH | -50.5 |
| AAPG Ascentage Pharma Group International | $1.4B | -6.3 | -236.8 | -144.8 | -270.2 | 170.9 | 3 | BEARISH | -56.5 |
| SNBIF SanBio Company Limited | $1.3B | -19.8 | -55.8 | -2935.2 | — | — | 3 | BEARISH | 0.0 |
| OMDA Omada Health | $1.2B | 282.9 | 1.8 | -1.5 | 6.0 | 404.7 | 7 | BEARISH | -27.4 |
| CVSGF CVS Group plc | $1.1B | 52.9 | 5.9 | 7.3 | 2.7 | -22.7 | 6 | BEARISH | 0.7 |
| PKBFF PeakBirch Commerce Inc. | $540M | -0.0 | -16609.0 | 16544.6 | -58.8 | -69.1 | 3 | BEARISH | 0.0 |
| DCTH Delcath Systems, Inc. | $500M | 1342.4 | 0.5 | -2.7 | 9.2 | 35.8 | 6 | BEARISH | 48.8 |
| GRDN Guardian Pharmacy Services, Inc. | $2.5B | 38.1 | 31.7 | 33.2 | 6.2 | 10.3 | 7 | BEARISH | 39.1 |
| BPMUF Basilea Pharmaceutica AG | $960M | 17.2 | 39.5 | 75.9 | 23.5 | 4.5 | 7 | BEARISH | 27.1 |
| BOIRF Boiron S.A. | $550M | 12.4 | 7.2 | 7.8 | 2.0 | 97.0 | 5 | BEARISH | 10.5 |
| HRMY Harmony Biosciences Holdings, Inc. | $2.1B | 12.2 | 20.5 | 35.7 | 28.9 | 24.3 | 5 | BEARISH | 27.9 |
| PANHF Ping An Healthcare and Technology Company Limited | $2.1B | 20.7 | 4.6 | 5.6 | 8.8 | 2.9 | 6 | BEARISH | -61.7 |
| RYHTY Ryman Healthcare Limited | $1.0B | -10.9 | -4.2 | -0.3 | -30.8 | 10.6 | 7 | BEARISH | -32.6 |
| CLYM Climb Bio, Inc. | $590M | -11.9 | -27.1 | -88.6 | — | — | 2 | BEARISH | 381.9 |
| MNPR Monopar Therapeutics Inc. | $470M | -30.8 | -19.5 | 523.8 | — | — | 2 | BEARISH | -9.7 |
| MEOBF Mesoblast Limited | $2.0B | -29.9 | -9.9 | -6.4 | -23.4 | 613.8 | 5 | BEARISH | -21.4 |
| PCVX Vaxcyte, Inc. | $9.5B | -8.0 | -36.5 | -66.4 | — | — | 0 | BEARISH | 37.9 |
| BIOGY BioGaia AB (publ) | $1.3B | 31.4 | 31.8 | 52.6 | 27.5 | 13.1 | 5 | BEARISH | 19.9 |
| MMED MiniMed Group, Inc. | $5.2B | — | — | — | — | — | — | BEARISH | — |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.2B | -26.5 | -64.8 | 65.7 | -258.2 | 12.2 | 4 | BEARISH | 52.5 |
| AMLX Amylyx Pharmaceuticals, Inc. | $3.4B | -19.8 | -74.7 | 2020.5 | — | 100.0 | 5 | BEARISH | 97.3 |
| MBX MBX Biosciences, Inc. Common Stock | $2.3B | -22.1 | -33.2 | 1634.0 | — | — | 2 | BEARISH | 210.6 |
| MLYS Mineralys Therapeutics, Inc. | $1.8B | -5.0 | -80.9 | 2274.6 | — | — | 2 | BEARISH | -47.3 |
| IMTX Immatics N.V. | $1.1B | -4.1 | -47.8 | -858.3 | -683.4 | -68.0 | 2 | BEARISH | -30.5 |
| LYPHF Luye Pharma Group Ltd. | $1.1B | 7.8 | 4.5 | 5.7 | 13.0 | -2.1 | 6 | BEARISH | 0.8 |
| TDVXF Dynavox Group AB (publ) | $900M | 28.7 | 39.7 | 17.2 | 12.8 | 8.8 | 8 | BEARISH | -29.1 |
| AKTS Aktis Oncology, Inc. | $850M | -15.9 | -29.9 | 276.4 | -713.5 | -36.1 | 5 | BEARISH | 365552.2 |
| ATTO Attovia Therapeutics, Inc. | $630M | -17.0 | -294.4 | -1137.2 | -4597.1 | -50.5 | 4 | BEARISH | 313.6 |
| OLMA Olema Pharmaceuticals, Inc. | $560M | -3.5 | -52.7 | 585.3 | — | — | 2 | BEARISH | -14.8 |
| BNTC Benitec Biopharma Inc. | $300M | -8.8 | -33.2 | 1840.8 | — | — | 3 | BEARISH | -34.9 |
| CSMYF COSMOS Pharmaceutical Corporation | $3.2B | 14.9 | 11.7 | 9.8 | 2.9 | 9.5 | 6 | BEARISH | -13.4 |
| TARS Tarsus Pharmaceuticals, Inc. | $3.2B | -66.0 | -13.7 | 268.1 | -10.7 | 105.2 | 5 | BEARISH | 5.7 |
| NHNKY Nihon Kohden Corporation | $3.1B | 19.0 | 7.8 | 7.9 | -1.6 | 2.6 | 9 | BEARISH | -18.3 |
| CSPHF CStone Pharmaceuticals | $1.4B | -15.0 | -51.4 | -340.2 | -123.0 | 135.6 | 5 | BEARISH | -15.4 |
| DRTSW Alpha Tau Medical Ltd. | $1.2B | -12.8 | -141.7 | -17.1 | — | — | 3 | BEARISH | 820.5 |
| SMSZF SMS Co., Ltd. | $700M | -14.7 | -40.8 | 31.1 | 18.4 | 6.9 | 6 | BEARISH | 0.0 |
| ZRSEF DocMorris AG | $520M | -10.2 | -30.1 | -29.3 | -8.9 | 11.0 | 2 | BEARISH | 0.0 |
| OSCR Oscar Health, Inc. | $8.0B | 17.8 | 34.3 | -9.6 | 7.4 | 42.8 | 7 | BEARISH | 55.1 |
| GHRS GH Research PLC | $1.2B | -20.4 | -18.8 | 2015.5 | — | — | 2 | BEARISH | 44.6 |
| DSGN Design Therapeutics, Inc. | $640M | -9.2 | -34.1 | 1787.8 | — | — | 1 | BEARISH | 59.0 |
| HNSBF Hansa Biopharma AB (publ) | $330M | -4.9 | 159.8 | 1182.7 | -541.7 | -3.7 | 2 | BEARISH | -28.2 |
| IDRSF Idorsia Ltd | $1.4B | -3.5 | 27.1 | -344.5 | -203.1 | -8.1 | 1 | BEARISH | 19.6 |
| VBIZF Viva Biotech Holdings | $400M | 13.9 | 4.5 | 4.2 | 8.0 | 2.9 | 7 | BEARISH | -35.1 |
| DNLI Denali Therapeutics Inc. | $2.9B | -6.7 | -54.9 | -281.7 | -3539.2 | — | 3 | BEARISH | 19.0 |
| CASBF CanSino Biologics Inc. | $1.4B | 399.2 | 0.8 | -1.2 | 11.0 | 32.5 | 7 | BEARISH | -39.1 |
| CRVS Corvus Pharmaceuticals, Inc. | $890M | -16.2 | -35.4 | -415.6 | — | — | 4 | BEARISH | 33.8 |
| GALNF Galenica AG | $5.0B | 27.6 | 11.2 | 6.8 | 3.1 | 6.2 | 4 | BEARISH | 32.2 |
| CLDX Celldex Therapeutics, Inc. | $2.3B | -6.7 | -43.9 | -13685.9 | -334104.5 | -98.1 | 1 | BEARISH | 8.4 |
| ALHC Alignment Healthcare, Inc. | $1.7B | 40.3 | 20.0 | -54.4 | 2.7 | 37.2 | 8 | BEARISH | -54.0 |
| ANIP ANI Pharmaceuticals, Inc. | $1.7B | 15.0 | 20.0 | 20.7 | 9.3 | 30.9 | 7 | BEARISH | -22.8 |
| NKTR Nektar Therapeutics | $1.1B | -5.7 | -35.8 | -29.2 | -401.0 | -27.2 | 3 | BEARISH | -38.4 |
| RGNX REGENXBIO Inc. | $440M | -1.9 | -137.6 | -368.4 | 21.0 | 12.0 | 2 | BEARISH | -46.8 |
| BLSM BlossomHill Therapeutics, Inc. | $430M | — | — | — | — | — | — | BEARISH | — |
| TECX Tectonic Therapeutic, Inc. | $390M | -4.5 | -33.8 | -6371.3 | — | — | 1 | BEARISH | 10.4 |
| TNGX Tango Therapeutics, Inc. | $3.9B | -26.7 | -21.3 | -253.2 | — | 121.5 | 3 | BEARISH | 186.1 |
| TLX Telix Pharmaceuticals Limited | $3.1B | 96.4 | 6.8 | -0.5 | 8.0 | -7.7 | 3 | BEARISH | -15.4 |
| PPTDF PeptiDream Inc. | $870M | -39.5 | -7.1 | -9.6 | -25.7 | 47.8 | 4 | BEARISH | -38.7 |
| WHTCF WELL Health Technologies Corp. | $770M | 163.0 | 0.5 | 5.4 | -2.7 | 38.6 | 6 | BEARISH | -20.2 |
| GNMLF Genomma Lab Internacional, S.A.B. de C.V. | $710M | 8.4 | 14.3 | 13.4 | 11.4 | 22.0 | 4 | BEARISH | -22.7 |
| AQST Aquestive Therapeutics, Inc. | $500M | -6.4 | 121.1 | 43.4 | -165.5 | 22.6 | 5 | BEARISH | -39.6 |
| IMVT Immunovant, Inc. | $5.9B | -10.4 | -80.1 | 707.5 | -2159.6 | — | 2 | BEARISH | 37.3 |
| EXETF Extendicare Inc. | $1.9B | 19.8 | 43.8 | 14.1 | 5.0 | 31.2 | 3 | BEARISH | 70.0 |
| ANRO Alto Neuroscience, Inc. | $860M | -9.3 | -49.2 | -201.4 | — | — | 3 | BEARISH | 90.5 |
| ABUS Arbutus Biopharma Corp | $830M | 5.4 | 89.6 | 86.7 | -507.2 | 1078.8 | 4 | BEARISH | -3.4 |
| GNNSF Genscript Biotech Corporation | $9.6B | -15.7 | -15.4 | 2.9 | -32.0 | 53.1 | 4 | BEARISH | 103.7 |
| HYPMY Hypera S.A. | $3.8B | 8.1 | 13.2 | 12.8 | 21.0 | 31.8 | 8 | BEARISH | -9.1 |
| NUVB Nuvation Bio Inc. | $1.6B | -10.4 | -47.8 | 70.2 | -198.3 | 1083.6 | 4 | BEARISH | -8.7 |
| AUTL Autolus Therapeutics plc | $410M | -1.5 | -132.9 | 451.5 | -85.6 | 292.0 | 3 | BEARISH | -1.2 |
| AUNA Auna S.A. | $380M | -16.9 | 0.8 | 4.5 | 2.4 | 9.2 | 7 | BEARISH | -21.6 |
| SMTI Sanara MedTech Inc. | $300M | -8.8 | -147.7 | 19.8 | -1.6 | 12.9 | 5 | BEARISH | 7.8 |
| TRLV Trulieve Cannabis Corp. | $1.8B | — | — | — | — | — | — | BEARISH | — |
| OCUL Ocular Therapeutix, Inc. | $1.4B | -5.0 | -73.0 | -31671.3 | -584.5 | -8.1 | 3 | BEARISH | -36.9 |
| BDULF Bangkok Dusit Medical Services Public Company Limited | $9.7B | 20.7 | 15.0 | 12.4 | 12.1 | 1.3 | 4 | BEARISH | -3.2 |
| OMER Omeros Corporation | $1.2B | 9.2 | -89.2 | 71.8 | 46.4 | — | 5 | BEARISH | 131.9 |
| AVBP ArriVent BioPharma, Inc. | $1.0B | -4.2 | -53.1 | 2345.1 | — | — | 3 | BEARISH | -19.3 |
| IRWD Ironwood Pharmaceuticals, Inc. | $570M | 4.5 | -55.3 | 93.9 | 45.4 | 26.2 | 7 | BEARISH | 121.5 |
| EPRX Eupraxia Pharmaceuticals Inc. | $450M | -7.1 | -68.6 | 8742.2 | — | — | 3 | BEARISH | 33.5 |
| VRNO Verano Holdings Corp | $370M | -1.4 | -4.5 | 1.5 | -6.2 | — | 3 | BEARISH | — |
| IBRX ImmunityBio, Inc. | $8.7B | -8.8 | 122.7 | 33.7 | -449.6 | 192.9 | 4 | BEARISH | 231.9 |
| CAMRF Camurus AB | $3.7B | 58.8 | 15.8 | 89.3 | 34.3 | -0.2 | 6 | BEARISH | -10.3 |
| ORIC ORIC Pharmaceuticals, Inc. | $1.4B | -6.7 | -39.8 | -102.9 | — | — | 3 | BEARISH | -30.6 |
| KSPHF Kissei Pharmaceutical Co., Ltd. | $1.0B | 11.2 | 6.5 | -1.9 | 20.2 | 10.7 | 6 | BEARISH | -2.4 |
| RAPP Rapport Therapeutics, Inc. Common Stock | $1.2B | -7.4 | -40.0 | 3981.5 | — | — | 4 | BEARISH | -15.0 |
| DRTS Alpha Tau Medical Ltd | $1.2B | -12.8 | -141.7 | -17.1 | — | — | 3 | BEARISH | 220.9 |
| MGTX MeiraGTx Holdings plc | $880M | 12.6 | 72.3 | 96.7 | 50.0 | 948.3 | 7 | BEARISH | 9.9 |
| RCUS Arcus Biosciences, Inc. | $2.3B | -4.6 | -89.2 | 309.6 | -222.0 | -55.3 | 0 | BEARISH | -0.9 |
| SGIPF Sugi Holdings Co.,Ltd. | $1.8B | 15.9 | 10.0 | 11.6 | 2.2 | 46.6 | 7 | BEARISH | 0.9 |
| NAMS NewAmsterdam Pharma Company N.V. | $2.3B | -9.5 | -36.8 | 8216.2 | -1732.9 | -88.9 | 2 | BEARISH | -41.5 |
| AVLN Avalyn Pharma Inc. Common Stock | $1.1B | — | — | — | — | — | — | BEARISH | — |
| APMD Apnimed, Inc. | $790M | — | — | — | — | — | — | BEARISH | — |
| CBIO Crescent Biopharma, Inc. | $480M | -1.8 | -107.7 | 1928.6 | — | — | 5 | BEARISH | 3.9 |
| NPCE NeuroPace, Inc. | $440M | -22.9 | -122.1 | -39.6 | -27.2 | 11.6 | 4 | BEARISH | 22.0 |
| KYTX Kyverna Therapeutics, Inc. | $330M | -2.0 | -87.2 | 14267.8 | — | — | 2 | BEARISH | -24.6 |
| KRYS Krystal Biotech, Inc. | $9.2B | 38.4 | 20.1 | 40.4 | 45.9 | 22.6 | 7 | BEARISH | 69.2 |
| NVCR Novocure Ltd | $1.7B | -10.7 | -43.2 | -93.1 | -8.5 | 11.0 | 6 | BEARISH | 4.3 |
| GERN Geron Corporation | $720M | -9.6 | -29.2 | -74.1 | -29.0 | 24.4 | 2 | BEARISH | -24.3 |
| MTLZF Metall Zug AG | $680M | -34.1 | -2.8 | -1.4 | -5.6 | -0.3 | 6 | BEARISH | 0.0 |
| HELP Helus Pharma Inc. | $630M | -2.6 | -56.3 | -143.0 | — | — | 2 | BEARISH | — |
| ZVRA Zevra Therapeutics, Inc. | $580M | 10.6 | 34.8 | -1356.4 | 22.1 | 119.4 | 6 | BEARISH | -7.0 |
| PHAT Phathom Pharmaceuticals, Inc. | $460M | -4.9 | 26.4 | 8.9 | -23.7 | 110.2 | 4 | BEARISH | -54.5 |
| FTH Faeth Therapeutics, Inc. | $440M | — | — | — | — | — | — | BEARISH | — |
| UFPT UFP Technologies, Inc. | $2.3B | 30.3 | 17.1 | 13.3 | 12.0 | 7.3 | 7 | BEARISH | 43.0 |
| NPRRF Nipro Corporation | $1.4B | — | — | — | — | — | — | BEARISH | 5.8 |
| TVTX Travere Therapeutics, Inc. | $4.7B | -111.7 | -151.8 | -21.0 | -20.5 | 77.1 | 6 | BEARISH | 70.8 |
| CURLF Curaleaf Holdings, Inc. | $1.8B | -61.0 | -4.2 | 0.5 | 3.7 | 2.7 | 7 | BEARISH | -1.5 |
| NVAX Novavax, Inc. | $1.6B | -6.7 | 323.7 | 29.2 | -94.2 | -61.6 | 2 | BEARISH | 18.6 |
| NWPHF Newron Pharmaceuticals S.p.A. | $410M | -6.6 | 83.9 | -32.1 | -513.4 | — | 1 | BEARISH | — |
| BKD Brookdale Senior Living Inc. | $2.4B | -17.1 | -362.1 | 10.3 | 3.2 | -2.3 | 6 | BEARISH | 14.1 |
| GTBIF Green Thumb Industries Inc. | $1.4B | 11.6 | 7.0 | 2.5 | 1.6 | 4.8 | 7 | BEARISH | -13.5 |
| SNDX Syndax Pharmaceuticals, Inc. | $1.2B | -5.5 | -255.9 | -270.9 | -67.8 | 222.3 | 4 | BEARISH | 9.2 |
| CTMX CytomX Therapeutics, Inc. | $510M | -5.2 | -37.8 | 305.9 | -1457.4 | -87.0 | 2 | BEARISH | -29.8 |
| ASMB Assembly Biosciences, Inc. | $400M | 37.2 | -0.0 | 56.2 | -28.8 | 125.1 | 4 | BEARISH | -31.0 |
| MPLT MapLight Therapeutics, Inc. | $340M | -1.5 | -57.5 | -366.6 | — | — | 2 | BEARISH | -56.5 |
| RADLY Raia Drogasil S.A. | $7.2B | 20.2 | 19.4 | 16.9 | 3.8 | 10.9 | 7 | BEARISH | -23.1 |
| RTEZ Rest Ez Inc. | $4.2B | — | — | — | — | — | — | BEARISH | 0.0 |
| IDYA IDEAYA Biosciences, Inc. | $3.4B | -17.7 | -16.2 | -42.9 | -1269.6 | 3244.7 | 4 | BEARISH | 4.9 |
| HCM HUTCHMED (China) Limited | $2.6B | 145.4 | 46.6 | 11.0 | 5.7 | -11.8 | 6 | BEARISH | -10.4 |
| DMPHF Dermapharm Holding SE | $2.4B | 13.8 | 25.6 | 13.0 | 8.1 | 0.5 | 5 | BEARISH | 20.6 |
| SLS SELLAS Life Sciences Group, Inc. | $2.3B | -48.9 | -39.6 | 55646.0 | — | — | 4 | BEARISH | 435.1 |
| PGEN Precigen, Inc. | $2.2B | -5.3 | -4640.4 | -30.1 | 36.5 | 1875.0 | 5 | BEARISH | 41.4 |
| ASCLF Ascletis Pharma Inc. | $770M | -7.8 | -28.4 | -7144.0 | — | -60.6 | 2 | BEARISH | -40.0 |
| ACHV Achieve Life Sciences, Inc. | $670M | -4.3 | -845.0 | 24.6 | — | — | 2 | BEARISH | 46.4 |
| NVCT Nuvectis Pharma, Inc. | $650M | -14.0 | -214.6 | 174.4 | — | — | 1 | BEARISH | 180.3 |
| NIKA Nika Pharmaceuticals Inc. | $370M | -4711.6 | 26.8 | 18.5 | — | 100.0 | 3 | BEARISH | 8.5 |
| CORT Corcept Therapeutics Incorporated | $9.3B | 166.2 | 8.1 | 3.1 | 16.5 | 16.0 | 6 | BEARISH | 18.9 |
| BLTE Belite Bio, Inc | $5.9B | -53.3 | -20.8 | -11.5 | — | — | 3 | BEARISH | 58.5 |
| YPHDF Ypsomed Holding AG | $5.7B | 24.1 | 31.1 | 17.4 | 22.5 | -2.3 | 8 | BEARISH | -8.1 |
| VRBCF Virbac S.A. | $3.2B | 18.7 | 13.6 | 12.7 | 11.4 | 3.9 | 5 | BEARISH | 10.8 |
| MEDGF Medacta Group S.A. | $2.7B | 33.3 | 17.1 | 9.8 | 11.4 | 8.9 | 4 | BEARISH | 63.9 |
| ORPEF Emeis | $2.3B | -4.5 | -19.0 | 3.2 | -5.4 | 40.2 | 5 | BEARISH | 0.0 |
| ARSUF Fagron N.V. | $2.0B | 19.1 | 16.7 | 10.8 | 8.4 | 11.8 | 4 | BEARISH | 9.8 |
| SNDA Sonida Senior Living, Inc. | $1.6B | -5.4 | -25.2 | -2.9 | -11.8 | 49.4 | 4 | BEARISH | 28.5 |
| MEDOF Medios AG | $1.3B | 23.8 | 2.1 | 2.8 | 0.6 | 10.0 | 6 | BEARISH | 0.0 |
| CSBTF Kuros Biosciences AG | $950M | 115.7 | 9.6 | 9.2 | 4.8 | 29.1 | 4 | BEARISH | -39.6 |
| IART Integra LifeSciences Holdings Corporation | $930M | 71.9 | 1.2 | 13.4 | 3.6 | 0.8 | 6 | BEARISH | -23.2 |
| IMMX Immix Biopharma, Inc. | $680M | -9.1 | -34.2 | 1509.2 | — | — | 4 | BEARISH | 139.8 |
| LXRX Lexicon Pharmaceuticals, Inc. | $630M | -9.7 | -40.2 | -99.7 | -4591.8 | -29.0 | 3 | BEARISH | 28.4 |
| CADL Candel Therapeutics, Inc. | $610M | -6.0 | -81.8 | 219.4 | — | — | 2 | BEARISH | 60.6 |
| MDXG MiMedx Group, Inc. | $570M | 97.9 | 2.9 | 5.8 | -23.1 | -2.4 | 6 | BEARISH | -41.3 |
| AVR Anteris Technologies Global Corp. | $570M | -2.2 | -75.1 | 3136.2 | -2884.3 | 31.1 | 5 | BEARISH | 16.6 |
| AVIR Atea Pharmaceuticals, Inc. | $320M | -2.0 | -58.1 | 974.6 | — | — | 3 | BEARISH | 31.4 |
| CYTK Cytokinetics, Incorporated | $8.5B | -8.4 | 329.8 | 811.2 | -622.8 | -17.2 | 2 | BEARISH | 1.8 |
| HBMHF HBM Holdings Limited | $1.3B | 12.7 | 24.1 | 53.0 | 53.0 | 54.6 | 4 | BEARISH | -38.1 |
| GPCR Structure Therapeutics Inc. | $1.2B | -7.0 | -20.2 | -1134.3 | — | — | 3 | BEARISH | -25.0 |
| RAFLF Raffles Medical Group Ltd | $1.2B | 22.4 | 5.8 | 7.3 | 8.2 | -2.8 | 7 | BEARISH | -20.0 |
| MCRPF MicroPort Scientific Corp. | $1.1B | 31.2 | 6.1 | -1.7 | 21.3 | -3.5 | 5 | BEARISH | -63.2 |
| ARDX Ardelyx, Inc. | $770M | -13.5 | -38.6 | -22.7 | -13.8 | 16.8 | 4 | BEARISH | -39.2 |
| XVIPY Xvivo Perfusion AB (publ) | $690M | 50.1 | 5.9 | 4.6 | 17.7 | 17.5 | 6 | BEARISH | — |
| SLBT SL Science Holding Ltd | $640M | — | — | — | — | — | — | BEARISH | — |
| PROK ProKidney Corp. | $470M | -2.6 | 9.2 | 13.2 | -18948.0 | 55.2 | 1 | BEARISH | -52.8 |
| SSII SS Innovations International, Inc. | $450M | -38.0 | -26.1 | -15.6 | -19.1 | 108.5 | 3 | BEARISH | -71.6 |
| BWAY BrainsWay Ltd. | $440M | 46.7 | 13.0 | 31.1 | 15.8 | 32.3 | 5 | BEARISH | 33.6 |
| CALZF PolyNovo Limited | $430M | 81.6 | 8.4 | 9.3 | 10.0 | 12.8 | 7 | BEARISH | -27.9 |
| SWDCF Swedencare AB (publ) | $370M | 35.2 | 1.2 | 1.7 | 3.9 | 1.4 | 7 | BEARISH | -46.5 |
| NHC National HealthCare Corporation | $3.7B | 23.4 | 13.1 | 12.6 | 9.9 | 6.9 | 8 | BEARISH | 75.9 |
| INBX Inhibrx Biosciences Inc. | $1.4B | -8.0 | -1773.6 | 55.8 | — | -100.0 | 4 | BEARISH | 24.5 |
| IRMD IRadimed Corporation | $1.1B | 46.1 | 23.5 | 50.1 | 25.5 | 11.2 | 6 | BEARISH | 8.8 |
| RMYHY Ramsay Health Care Limited | $9.2B | 41.0 | 6.6 | 4.2 | 1.8 | 4.2 | 7 | BEARISH | 85.2 |
| HAWPY Haw Par Corporation Limited | $3.0B | 12.4 | 5.2 | 1.6 | 93.0 | -12.8 | 4 | BEARISH | -20.4 |
| CHSYF China Medical System Holdings Limited | $2.7B | 13.5 | 8.6 | 9.0 | 21.9 | 9.2 | 4 | BEARISH | -17.8 |
| URGN UroGen Pharma Ltd. | $1.7B | -17.0 | 86.5 | 119.0 | -19.8 | 169.5 | 2 | BEARISH | 61.9 |
| ELEAF EL.En. S.p.A. | $1.4B | 14.0 | 13.2 | 29.1 | 6.0 | 25.8 | 8 | BEARISH | 37.9 |
| MDCLF MedinCell S.A. | $1.1B | -29.2 | 472.2 | 81.6 | -152.1 | -14.8 | 3 | BEARISH | 333.5 |
| INMD InMode Ltd. | $800M | 10.7 | 12.3 | 44.5 | 17.9 | -6.7 | 5 | BEARISH | -14.6 |
| ANL Adlai Nortye Ltd. | $560M | -5.2 | -22.4 | -317.5 | -36.3 | 223.4 | 4 | BEARISH | 575.5 |
| GNFTF Genfit S.A. | $470M | -5.6 | -5084.0 | -322.7 | -124.0 | 27.5 | 3 | BEARISH | 153.5 |
| VREOF Vireo Growth Inc. | $310M | -3.9 | -4.6 | -0.7 | -0.0 | — | 3 | BEARISH | — |
| ARTV Artiva Biotherapeutics, Inc. | $300M | -1.3 | -36.6 | -954.6 | — | — | 3 | BEARISH | -15.1 |
| AXSM Axsome Therapeutics, Inc. | $7.6B | -38.4 | -245.1 | 859.1 | -23.5 | 56.9 | 5 | BEARISH | 6.6 |
| REGMF RemeGen Co., Ltd. | $5.6B | 9.3 | 108.3 | 139.6 | 83.4 | 283.6 | 7 | BEARISH | -7.7 |
| LABFF Laboratorios Farmaceuticos Rovi, S.A. | $3.4B | 16.9 | 29.3 | 19.6 | 39.1 | 3.3 | 6 | BEARISH | -25.9 |
| VKTX Viking Therapeutics, Inc. | $3.1B | -5.3 | -88.9 | 495.6 | — | — | 1 | BEARISH | -29.4 |
| AMFPF Amplifon S.p.A. | $3.0B | 42.7 | 5.7 | 7.2 | 6.4 | -0.2 | 5 | BEARISH | -36.0 |
| ADDLF AddLife AB (publ) | $1.9B | 34.7 | 11.3 | 7.0 | 4.9 | 1.1 | 4 | BEARISH | -62.5 |
| GENSF Genus plc | $1.8B | 5.4 | 45.4 | 9.0 | 80.4 | -3.8 | 5 | BEARISH | -19.4 |
| VIMGF Vimian Group AB (publ) | $1.5B | 49.1 | 5.4 | 6.4 | 7.4 | 8.9 | 7 | BEARISH | -8.0 |
| SHPHF Sihuan Pharmaceutical Holdings Group Ltd. | $1.1B | 18.4 | 5.7 | 8.4 | 19.4 | 24.4 | 6 | BEARISH | 20.0 |
| CHIZF China Traditional Chinese Medicine Holdings Co. Limited | $820M | -4.9 | -4.9 | 0.0 | -14.3 | 5.6 | 6 | BEARISH | -40.3 |
| TGRNF Tong Ren Tang Technologies Co. Ltd. | $660M | 10.6 | 4.1 | 12.2 | 8.2 | -18.2 | 6 | BEARISH | -43.0 |
| CRWRF Craneware plc | $620M | 25.8 | 6.0 | 6.8 | 9.7 | 4.2 | 7 | BEARISH | -43.9 |
| EVOTF Evotec SE | $590M | -2.7 | -26.1 | -14.9 | -32.5 | -7.7 | 2 | BEARISH | -54.3 |
| KSRBF Kossan Rubber Industries Bhd | $480M | 17.0 | 5.0 | 8.5 | 11.3 | 1.0 | 5 | BEARISH | -43.2 |
| AGMB AgomAb Therapeutics N.V. American Depositary Shares | $450M | — | — | — | — | — | — | BEARISH | — |
| AVCTF Avacta Group Plc | $420M | -6.7 | -2083.2 | -753.6 | -33970.3 | -99.7 | 5 | BEARISH | -18.7 |
| CYH Community Health Systems, Inc. | $410M | -1.2 | 19.9 | -79.1 | 1.7 | 77.2 | 5 | BEARISH | -39.7 |
| ALT Altimmune, Inc. | $410M | -2.6 | -28.9 | -43.1 | — | 55.0 | 4 | BEARISH | -47.0 |
| AVTX Avalo Therapeutics, Inc. | $370M | -1.4 | -36.3 | -148.4 | — | -86.6 | 4 | BEARISH | -60.4 |
| CAPR Capricor Therapeutics, Inc. | $340M | -2.5 | -73.7 | -107.5 | — | -100.0 | 3 | BEARISH | 0.8 |
| TLRY Tilray Brands, Inc. | $310M | -1.9 | -8.8 | -3.4 | -16.8 | -16.9 | 3 | BEARISH | -81.7 |
| SFOSF Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | $5.8B | 18.0 | 10.7 | 6.3 | 8.4 | 53.9 | 7 | BEARISH | -34.2 |
| TRSBF 3SBio Inc. | $4.3B | 3.5 | 37.1 | 80.3 | 25.3 | 93.8 | 7 | BEARISH | -51.7 |
| BRCTF BioArctic AB | $2.6B | 269.1 | 5.2 | 77.4 | -4.5 | -46.1 | 3 | BEARISH | -8.6 |
| TMDX TransMedics Group, Inc. | $2.5B | 15.2 | 36.3 | 18.7 | 7.7 | 25.8 | 3 | BEARISH | -49.5 |
| ZLDPF Zealand Pharma A/S | $2.4B | 5.9 | 16.3 | 57.2 | 87.2 | -49.2 | 3 | BEARISH | -54.1 |
| INCPF InnoCare Pharma Limited | $2.4B | 19.1 | 12.6 | 45.8 | 23.1 | 108.5 | 4 | BEARISH | -50.9 |
| ULIHF The United Laboratories International Holdings Limited | $1.9B | 21.1 | 3.3 | 4.4 | 5.6 | -16.6 | 4 | BEARISH | -49.9 |
| PHMMF Pharma Mar, S.A. | $1.6B | 21.0 | 24.9 | 35.9 | -2.0 | 15.5 | 7 | BEARISH | -16.4 |
| FDMDF 4DMedical Limited | $1.6B | -8.7 | -174.5 | 43.4 | -1194.8 | 20.5 | 3 | BEARISH | 79.9 |
| BCAX Bicara Therapeutics Inc. Common Stock | $1.1B | -3.0 | -41.0 | 583.9 | — | — | 2 | BEARISH | -42.6 |
| LFTSF LifeTech Scientific Corporation | $1.0B | 105.4 | 7.3 | 6.9 | -5.7 | 103.7 | 4 | BEARISH | -14.3 |
| TTALF Terveystalo Oyj | $910M | 13.2 | 10.3 | 6.3 | 2.1 | -8.7 | 4 | BEARISH | -44.5 |
| IVEVF Inventiva S.A. | $750M | -6.2 | -988.4 | -371.6 | -347346.6 | -99.7 | 3 | BEARISH | -22.8 |
| INRLF Valneva SE | $640M | -2.8 | -118.0 | -54.8 | -89.3 | -27.2 | 1 | BEARISH | -44.9 |
| NNCSF Nanosonics Limited | $620M | 50.8 | 8.3 | 15.6 | 8.1 | 2.4 | 4 | BEARISH | -39.9 |
| SPRY ARS Pharmaceuticals, Inc. | $400M | -1.6 | -210.3 | -424.3 | -185.2 | 4.1 | 2 | BEARISH | -61.8 |
| EIKN Eikon Therapeutics, Inc. Common Stock | $390M | — | — | — | — | — | — | BEARISH | — |
| DMTRF 3-D Matrix, Ltd. | $310M | 12.4 | 75.0 | 31.1 | 9.4 | 57.0 | 6 | BEARISH | 61.3 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
VIR vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F